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1  Introduction
1.1 The glioblastoma
Brain  tumours,  especially  malignant  gliomas  belong  to  the  most  aggressive  human
cancers with a short survival time. Despite the numerous advances in neurosurgical operative
techniques, adjuvant chemotherapy, and radiotherapy (1-3), the therapeutic progress is still
limited. Even the chemotherapeutic drugs most effective in glioblastoma, nitrosurea, platinum
compounds, or temozolomide, increase the survival time of patients only slightly (4). Reasons
responsible for the aggressive character of glioma include rapid proliferation, diffuse growth,
and invasion into distant brain areas in addition to extensive cerebral edema and high level of
angiogenesis.
Gliomas are a class of tumours that develops from glial (neuroepithelial or support) cells.
Astrocytes, ependymal, and oligodendroglial cells are all examples of glial cells that compose
the supportive tissue of the brain. Gliomas comprise nearly one-half of primary brain tumors and
one-fifth of all primary spinal cord tumours. Contemporary classification of gliomas is based on
the World Health Organization (WHO) system, which classifies the tumors according to the cell
of origin and histologic features identified by the pathologist or neuropathologist. Low-grade
gliomas are slowly growing, and are assigned either a I or II grade. From a practical standpoint,
grade I tumours (such as the pilocytic astrocytoma) are usually excluded from conversation
dealing with gliomas, as they constitute a distinctive pathologic and clinical entity. High grade
(malignant) gliomas grow much more quickly, and are assigned either a III (anaplastic) or IV
(glioblastoma multiforme) grade. Combined, grade III and IV gliomas represent about 40% of all
primary brain tumours in patients aged 40-49 years, and 60% in patients older than 60 years. In
most clinical series, grade III tumours comprise approximately 10% and grade IV 90% of the
total number of high grade, malignant primary brain tumours.
In order to treat gliomas, models systems are necessary to evaluate the therapeutic value of the
different potiential drugs. In this perspective, rat brain tumour models have been widely used in
experimental neuro-oncology for almost three decades. The rat models that are available have
provided a wealth of information on in vitro and in vivo biochemical and biological properties of
brain tumours and their in vivo responses to various therapeutic modalities. Ideally, valid brain
tumour models should be derived from glia cells, be weakly or non-immunogenic, and their
response to therapy, or lack thereof, should be similar to human brain tumours (81).Introduction
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Before the effects of the potential therapeutic compounds are analyzed in rat tumour models,
their efficiency has to be characterized in cell culture systems. The glioma most commonly used
tumour cell lines are: GS-9L, RG-2 and F-98. GS-9L gliosarcoma, an immunogenic tumour,
was chemically induced in an inbred Fischer rat, has been one of the most widely used of all rat
brain tumour models. The F-98 and RG-2 gliomas were both chemically induced tumours that
appear to be either weakly or non-immunogenic (81).
It is important to evaluate the efficiency of the therapeutic drug to kill the tumour cells, as well its
delivery to the target tissue. But successful entry of therapeutic drugs into the brain is very rare
because the blood-brain-barrier (BBB) makes the brain practically inaccessible for lipidinsoluble
compounds (hydrophilic) such as polar molecules and small ions. The delivery of the cancer
drug through the BBB is therefore one of the major obstacles in glioma treatment.
1.2 Mechanisms conferring drug resistance in glioma treatment
1.2.1 The Blood-Brain Barrier
One of the most important fields studied in drug targeting is the targeting to the brain due
to its complexity, and only very few approaches are successful.
The brain is a delicate organ with very efficient mechanisms to protect it. Unfortunately, the
same mechanisms that maintain its homeostasis and thus protect it against intrusive chemicals
can also inhibit the access of therapeutic agents.
Many existing pharmaceuticals, which are potentially effective, are ineffective in the treatment of
brain diseases due to the inability to effectively deliver and sustain them within the brain. This
failure of systematically delivered drugs to effectively treat many CNS diseases, such as brain
tumours, can be explained by a number of biological barriers that inhibit or hinder the drug
delivery to the brain. These barriers are: the blood-brain-barrier, the blood-cerebrospinal fluid
barrier, and the blood-tumour-barrier.
The  Blood-brain  barrier  (BBB),  which  is  formed  by  the  tight  junctions  within  the  capillary
endothelium  of  the  brain,  forms  a  formidable  barrier  to  the  CNS  inhibiting  the  delivery  of
therapeutic  agents  (mostly  with  high  molecular  weight  and/or  hydrophilic  drug).  Although
selective transport mechanisms are present in the BBB such as diffusion, carrier-mediated
transport,  receptor-mediated,  adsorptive  and  fluid-phase  endocytosis,  the  transport  of
therapeutic agents via systemic mechanisms is limited. Principal mechanisms involved in the
restriction of brain drug uptake by the BBB include: (1) the absence of paracellular openings, (2)Introduction
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the lack of pinocytosis, and (3) the presence of significant protein efflux pumps. Therefore,
important research is dedicated to develop methods and technologies to circumvent the BBB
for brain drug delivery.
Figure 1. A schematic picture of the blood-brain-barrier with astrocytes associated
In order to overcome the limited access of drugs through the BBB to the brain, different delivery
methods have been developed. Many of these methods are characterized by the manipulation
of the BBB by temporary disruption of tight junctions to allow paracellular movement by way of
osmotic opening (13, 14) or by the use of biologically active agents (e.g. histamine, serotonin,
free oxygen radicals, calcium entry blockers, etc.), (15, 16). The problem with this method is
that it is very invasive because it also allows the free passage of non-desired drug, resulting in a
high toxicity of the brain.
Other important factors in limiting the entry of drugs into the brain are their physico-chemical
properties (e.g. hydrophilicity, lipophilicity, hydrogen bonding potential). These characteristics
largely determine the passive transport of drugs across the BBB. The lack of efficacy of some
drugs such as cisplatine and doxorubicin against gliomas has been attributed to their lack of
lipid solubility. This is responsible for the increased focus on lipid-soluble drugs in glioma
treatment. However, this property does not necessarily ensure a passage through the BBB,Introduction
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because the BBB is further reinforced by the presence of significant protein efflux pumps,
represented by a high concentration of P-glycoprotein (Pgp). Pgp is an active drug efflux
transporter protein, which is in the luminal membranes of the cerebral capillary endothelium.
This efflux transporter actively removes a broad range of drug molecules from the endothelium
cell cytoplasm before they cross into the brain.
Figure 2.  Properties of the transport in the blood-brain-barrier
The presence of P-gp in tumours causes multidrug resistance (MDR), and P-gp in the BBB is
also responsible for multidrug resistance (MDR) in the case of brain tumours. Using P-gp
inhibitors in cancer therapy can therefore be beneficial in two ways. The pharmacokinetics of
the therapeutic drugs can change and particularly, CNS concentrations can increase. The
intracellular drug concentration in brain tumours can be increased (provided that the inhibitor is
distributed to the brain tumour). The P-gp protein will be introduces in detail in chapter 1.3.Introduction
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1.2.2 The Tumour resistance
As mentioned before, the insufficient response to anti-cancer drugs is caused in part by
the inaccessibility of the brain for most chemotherapeutical compounds due to limited transport
through the blood-brain barrier. But the BBB is only one obstacle, which has to be overcome in
order to successfully treat brain tumours.
Therapeutic anticancer drugs must reach tumours by overcoming problems such as drug
resistance at the tumour level due to physiological barriers (non-cellular mechanism) and drug
resistance at the cellular level (cellular mechanism). In addition, they must successfully have the
following attributes: distribution, biotransformation and clearance of anticancer drugs in the
body. There are different mechanisms by which a tumour can be resistant to any therapeutic
drug. This resistance is the cause of frequent failure in chemotherapy treatment with any
chemotherapeutic drug.
The mechanisms of tumour resistance can be classified as
•  Non-cellular drug resistance mechanisms could be due to poorly vascularized tumour regions,
which can effectively reduce drug access to the tumour and thus protect it from the cytotoxicity
of the drug. The acidic environment in tumours can also confer a resistance mechanism against
basic drugs. These compounds would be ionized, preventing their internalization across the
membrane cellular.
•  Cellular drug resistance mechanisms compromise altered activity of specific enzyme systems,
altered apoptosis regulation, or transport based mechanisms, like P-glycoprotein efflux system,
responsible for the multidrug resistance (MDR), or the multidrug resistance associated protein
(MRP).
Another problem faced by the use of anticancer drugs is their toxicity to both, tumour and
normal cells, resulting in a limited efficacy of chemotherapy due to significant side effects.
Furthermore, until recently, frequently repeated doses of pharmaceutically active agents were
required for patient treatment to maintain desired drug levels and thereby also prolonged the
significant side effects of these drugs.
All of the above mentioned facts favoured the introduction of controlled drug release delivery
formulations,  such  as  nanoparticles,  liposomes,  microspheres,  etc. Controlled-release
technology has attracted much attention since it is possible to overcome such non-cellular and
cellular based mechanisms of resistance. Moreover, it is possible to increase the selectivity of
drugs  to  cancers  cells  reducing  their  toxicity  towards  normal  tissues  by  means  of  theseIntroduction
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formulations. Therefore, the development of drug carriers for controlled release of drugs and
targeting has been extensively studied and it was shown that drugs bound to the surface-
modified nanoparticles are able to cross impermeable barriers such as the BBB. The use of
drug carrier systems will be introduced in more detail in chapter 1.4.
1.3 The P-glycoprotein (P-gp).
The resistance of tumour cells to multiple drugs, referred to as multidrug resistance
(MDR), is a major obstacle in the successful treatment of various human cancers. In some types
of tumours, MDR is inherent, while in others it is usually acquired. The two best-described
transporters mediating MDR are P-glycoprotein (P-gp) and the multidrug-resistance protein
(MRP) (37-39). Although both are members of the large ATP binding cassette (ABC) superfamily
of transport ATPases, one of the largest protein families found in all phyla. Both proteins are
located in the plasma membrane they share less than 15 % amino acids identity (39).
The transport protein P-gp is located on the luminal side of the brain capillary endothelium and
acts as a transmembrane pump, which removes drugs from the cell membrane and cytoplasm.
ATP hydrolysis provides the energy for its active drug transport, which can occur against a
steep concentration gradient. P-gp is the product of the MDR1 gene (mdr1 and mdr1b in
rodents, and MDR1 in humans), which can be phosphorylated and localized in the plasma
membrane as glycosylated transmembrane protein (57).Introduction
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Figure. 3 P-gp Structure
P-gp has been shown to channel the ATP-mediated extrusion of MDR drugs, an activity that
can be inhibited by P-gp modulators in intact cells. However, P-gp modulators do not inhibit
multidrug-resistant associated protein MRP-dependent drug efflux (40). The discovery of P-gp
modulators  capable  of  reversing  MDR  in  cells  overexpressing  P-gp  raised  hope  that  the
administration of these modulators along with chemotherapeutics agents could overcome the
MDR phenomenon. But the treatment with P-gp modulators was unsuccessful due to the fact,
that MDR is not solely mediated by P-gp and additional mechanisms exist which cannot be
reversed by P-gp modulators (41-44).
A typical ABC transporter generally consists of at least one evolutionarily conserved ABC, also
known as NBD (Nucleotide Binding Domain) with about 215 amino acids, as well as several
predicated α-helical TMD (Transmembrane Domains). The NBD and TMD are normally arranged
in a duplicated forward (TMD6-NBD) 2 (see Fig.3) or reverse (NBD-TMD) 2 configurations,
although some other arrangements exist.
Molecules interacting with P-gp may be classified as substrates or antagonists (inhibitors).
Cancer drugs frequently are P-gp substrates, but do not block the transport of other substrates
while compounds in the antagonist or inhibitor groups, which fail to be transported, prevent the
transport of other compounds.Introduction
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Table 1. P-gp substrates and inhibitors
A.     P-gp substrates (Chemicals transported by P-gp)
            Cancer drugs
     Doxorubicin
     Daunorubicin
     Vinblastine
     Vincristine
     Actinomycin D
     Paclitaxel
     Teniposide
     Etoposide
Immunosuppressive drugs
     Cyclosporin A
Lipid-lowering agent
     Lovastatin
Antihistamine
     Terfendine
Steroids
     Aldosterone
     Hydrocortisone
     Cortisol
     Corticosterone
     Dexamethasone
Dopamine antagonist
     Domperidone
HIV protease inhibitors
     Amprenavir
     Indinavir
     Nelfinavir
     Ritonavir
     Saquinavir
Cardiac drugs
     Digoxin
     Quinidine
Antiemetic
     Ondansetron
Anti-diarrheal agent
     Loperamide
Anti-gout agent
     Colchicine
Antibiotic
    Erythromycin
Anti-helminthic agent
     Ivermectin
Anti-tuberculuos agent
     Rifampin
Florescent dye
     Rhodamine-123Introduction
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B.     P-gp Inhibitors (Chemicals that block P-gp-mediated transport)
Cyclopropyldibenzosuberane
Immunosuppressant
     Cyclosporin A
     Valspodar (PSC833)
HIV protease inhibitors
     Ritonavir
     Saquinavir
     Nelfinavir
Cacium Channel Blocker
     Verapamil
Anti-estrogen cancer agent
     Tamoxifen
Antiarrhythmic
     Quinidine
Antifungal agent
     Keteconazole
Sedative
     Midazolam
P-gp activity is dependent on the signal transduction pathway and is connected to protein
kinase C (PKC). PKC phosphorylates P-gp, and overstimulation of PKC results in an increase of
Pgp-mediated substrate movement. PKC inhibitors produce a built-up of toxic chemicals in
MDR cells expressing P-gp, however, PKC inhibitors are also known to interact directly with the
Pgp  protein.  P-gp  activity  can  be  detected  by  different  methods.  One  of  them  is  the
measurement of ATP activity
Figure 5. Doxorubicin transport mechanism in chemosensitive cancer cells and
chemoresistant cancer cells.Introduction
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The cancer drug doxorubicin is one of the therapeutic candidates for brain tumours, which has
proven to be effective in glioblastome cell lines (17). But doxorubicin lacks the ability to cross
the BBB because it is a P-gp substrate. For this reason, a strategy, which emerged to enhance
the drug delivery of doxorubicin in the brain, was the administration in a formulation that may
overcome P-glycoprotein-mediated efflux. One option would be the use of a drug delivery
system to deliver doxorubicin to glioma cells lines.
1.4 Nanoparticles as a drug delivery system
1.4.1 Features of a drug delivery system
A  considerable  interest  was  established  in  recent  years  in  the  development  of
biodegradable carriers for effective delivery of therapeutic molecules at a controlled rate to the
required site in the body. Such a delivery is assumed to avoid the unwanted effects of drug
molecules  because  of  controlled  biodistribution.  Polymeric  nanoparticles  are  one  of  the
promising drug delivery devices, which could meet these requirements. The requirements for an
ideal delivery system are listed below.
Properties of an ideal delivery system
•  Selectivity: delivery of the drug preferentially to tumour cells or an enhanced effect on the
desired site.
•  Controlled/sustained rate of release
•  Low immunogenicity (not causing immune responses and hypersensitivity).
•  Scope of disease
•  Pharmaceutically acceptable characteristics (stability, administration, biodegradability, and ease
of sterilization).
Nanoparticles as a delivery system are able to efficiently transport therapeutic drugs, which are
unable  to  across  cellular  membranes  and  other  types  of  biological  barriers  due  to  their
physicochemical properties, such as lipophilicity and molecular weight. Drugs or compounds
that are not ionized at physiological pH, lipophilic, and of low molecular weight are able to
across the BBB by diffusion mechanisms. But others essential compounds, such as amino
acids, neuropeptides, and hexoses, normally need specific carries to permeate into the brain,
and for many others therapeutic drugs it is difficult to cross these biological barriers and toIntroduction
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internalize into cells. Therefore the use of this delivery system, such as nanoparticles has been
used in a number of studies to obtain a high efficiency in certain pharmacological treatment and
to increase the drug concentration in the target tissues.
1.4.2 Poly(butyl cyanoacrlate) nanoparticles.
Nanoparticles  are  nanosized  polymeric  colloidal  particles  with  a  therapeutic  agent
encapsulated within the polymeric matrix, or adsorbed, or conjugated onto the surface of the
nanoparticle. They are made of natural or synthetic polymer ranging in size between 10-1000
nm  (34).  Nanoparticles  can  be  prepared  from  synthetic  biodegradable  polymers  by
polymerization techniques of suspension, emulsion, or micelle polymerization. Various polymers
have been tested in drug delivery research. Poly(butyl cyanoacrylate) nanoparticles meet ideal
requirements  for  targeting,  it  is  for  instance  biodegradable,  has  the  ability  to  alter  the
biodistribution  of  drugs  and  is  easy  to  synthesize  and  purify.  Furthermore,  the  use  of
biodegradable  polymeric  nanoparticles  for  controlled  release  of  anticancer  drugs  has  the
advantages of enhancing the drug therapeutic efficacy and reducing drug systemic side effects.
The nanoparticles used in this work are made from butyl cyanoacrylate monomer by emulsion
polymerization. This reaction involves the dispersion of the monomer liquid, butyl cyanoacrylate,
in an aqueous phase to form particles.
The employment of poly(butyl cyanoacrylate) nanoparticles have previously been shown to
facilitate  the  transport  of  doxorubicin  into  the  brain  (76).  Moreover,  this  particles  very
significantly increased the survival time of rats with intracranial transplanted glioblastoma 101/8
and even led to long-term remission in 25% of the animals (72). Consequently, poly(butyl
cyanoacrylate) nanoparticles were successful in enabling the treatment of glioma tumours, as
also shown in vivo experiments by Kreuter et al. 2003 (33). Unfortunately, the mechanism by
which  the  drug  encapsulated  in  the  nanoparticles  reached  the  brain  is  presently  not  fully
elucidated.Introduction
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1.4.3 Surfactants as surface modifications of nanoparticles
As  already  indicated,  the  association  of  cytostatic  drugs  to  nanoparticles  leads  to
modifications of the drug biodistribution profile, which can improve the efficacy. However, one
of the major problems in targeted drug delivery is the rapid opsonization and uptake of the
nanoparticles by the mononuclear phagocytes system (MPS) (58). Once in the bloodstream,
nanoparticles are opsonized and cleared by macrophages, resulting in a decreased efficacy on
the target cells or tissues. The tendency of MPS organs to capture nanoparticles especially
occurs in those nanoparticles, which have not undergone any modification of their surface. They
are  called  non-modified  nanoparticles.  The  predisposition  of  MPS  macrophages  for
endocytosis/phagocytosis provides an opportunity to efficiently deliver therapeutic agents to
these cells and to enhance this specific anticancer drug efficacy, using these non-modified
nanoparticles.
The  usefulness  of  non-modified  nanoparticles  is  limited  by  their  massive  capture  by  the
macrophages of the MPS, therefore modification of nanoparticles is necessary to target to other
types of tumours. The ability of cells of the MPS to capture the nanoparticles depends on the
characteristics of the nanoparticle surface, such as charge and hydrophobicity surfaces. It is
possible to modify the surface of the nanoparticles to avoid capture by the MPS, protecting the
nanoparticles from phagocytosis (36). In modified nanoparticles, the surface characteristics and
the size of the nanoparticles are the key for their biological fate. Larger particles are filtered out
by the first capillary bed. A small size seems to improve the reduction in opsonization reactions
and subsequent removal by macrophages. Particles smaller than 100 nm, with hydrophilic
surfaces appear undergo relatively less opsonization and clearance by MPS uptake (102).
The  coating  of  the  surface  with  surfactants  has  been  studied  with  the  objective  of  the
development of the modified nanoparticles. The use of hydrophilic surfactants to coat the
surface creates a hydrophilic surface around the nanoparticles and avoids the capture of
nanoparticles by macrophages, giving long-circulating properties (36). The long-circulating
carriers thereby also increase the possibility of the nanoparticles to reach the brain (83; 20).
Thus,  the  coating  of  the  nanoparticles  surface  with  non-ionic  surfactants  promotes  an
enhancement of the internalization of the nanoparticles into cells (12, 36, 56).
A  hydrophilic  surface  can  be  obtained  by  adsorbing  hydrophilic  surfactants,  such  as
polysorbate 80 on the nanoparticles surface or using block/branched copolymers, such as
poloxamines and poloxamers. Polyethylene oxide (PEO) or poly ethylene glycol (PEG) are theIntroduction
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most  successful  non-ionic  hydrophilic  polymer  moiety  employed  for  this  purpose  (36).
Poloxamers consist of two ethylene oxide (EO) polymers attached to the ends of one propylene
oxide (PO) polymer. Poloxamines consist of four EO polymers attached to four PO polymer and
all four are coupled to an ethylene diamine core.
All  these  surfactants,  because  of  their  structure  and  properties,  are  used  to  modify  the
nanoparticle surface. However, the chemical nature of the coating surfactant is of importance,
because poloxamine 908-coated nanoparticles showed long-circulating characteristics but
failed to increase nanoparticle brain concentration (98), whereas doxorubicin adsorbed onto
polysorbate 80-coated nanoparticles was successfully delivered into the brain (76, 33, 72).
Polysorbate 80 so far is the most successful surfactant for brain delivery (33, 34). Overcoating
the  surface  with  polysorbates  has  resulted  in  an  increased  transport  of  nanoparticles-
associated drugs across the BBB, allowing targeting to the brain after intravenous injection (35).
The mechanism responsible for this enhancement in the transport of the nanoparticles is not yet
completely elucited. It is possible that polysorbate present on the nanoparticles surface acts as
an  anchor  for  apolipoprotein  E  (present  in  plasma),  resulting  in  its  adsorption  onto  the
nanoparticles. The particles thus would mimic LDL particles and interact with LDL receptors on
endothelial cells in the brain capillaries leading to their cellular uptake (35). Others authors (79,
80, 101) indicated polysorbate 80 as a surfactant able to inhibit the efflux pump protein, P-
glycoprotein (P-gp), mainly localized in the endothelial cells, and consequently it would allow the
internalization of the nanoparticles and/or the drug by blocking its P-gp-mediated transport.
Usually, the mode of attachment of these substances onto the nanoparticle surface often
involves physical adsorption. For instance, the polymeric surfactants of the poloxamers and
poloxamines  series  can  attach  themselves  onto  the  surfaces  of  particles  via  their  central
hydrophobic  region  (polyoxypropylene  or  polyoxypropylene  ethylene  diamine  oxide
respectively),  while  leaving  the  hydrophilic  portion  (ethylene  oxide)  protruding  out  into  the
surrounding medium.
Polysorbate 80, poloxamer 188, and poloxamine 908, three non-ionic surfactants that provide
hydrophilic properties to the nanoparticle system, provoked different effects on the properties of
the nanoparticles. As above already mentioned, polysorbate 80-nanoparticles were able to
overcome  the  blood-brain-barrier  (72),  whereas  poloxamer  188  and  poloxamine  908  only
provided long-circulating properties to the nanoparticles system (97, 98). For this reason, in the
present study these three surfactants were used to coat poly(butyl cyanoacrylate) nanoparticles
(PBCA-NP) to analyse their effect on the cytotoxicity of the Dox-PBCA-NP analysed.Introduction
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In  summary,  nanoparticles  may  provide  different  opportunities  for  targeting  by  surface
modifications, which would allow specific biochemical interactions with the proteins/receptors
expressed on the targeted cells. Thus, nanoparticles represent an emerging tool for intracellular
drug targeting of insoluble and sensitive drugs (such as proteins, oligonucleotides, or DNA).
Nanoparticles not only act as an effective carrier for such drugs, protecting them from the
undesirable physiological conditions, but also may allow a selective and controlled release of
the drugs at the target sites.
This is of particular importance in cancer chemotherapy, where cellular uptake of drugs is
limited due to the removal of the drugs by efflux protein pumps, such as P-glycoprotein.
Anticancer drugs encapsulated in nanoparticles cannot be recognized by this efflux mechanism
and therefore could circumvent the multidrug resistance.
1.5 The chemotherapeutic agent doxorubicin
Doxorubicin, an anthracycline antibiotic, is one of the most important anticancer drugs.
Anthracycline antibiotics are very broad-spectrum antitumor drugs and very effective neoplastic
agents, which are widely used clinically. However, these drugs induce many dose-limiting
adverse effects such as cardiac myopathy, alopecia, etc. In order to minimize these adverse
affects in clinical cancer chemotherapy, anthracyclines must be selectively transported into
tumour cells. To reach these selective target cells or tissues, carrier systems for these drugs
have  been  developed  (nanoparticles, nanocapsules,  and liposomes). Moreover, hydrophilic
molecules such as anthracycline antibiotics show a restricted transport through the cellular
membrane, thus nanoparticles also could be used to overcome the restriction of the transport
through biological membranes. For instance, doxorubicin, which is mainly hydrophilic, leads to
minimal drug internalization through the cellular membrane and is unable to overcome biological
barriers such as the blood-brain-barrier. Therefore, it does not reach the brain after systemic
administration. Due to this fact, free doxorubicin cannot successfully be used for the treatment
of brain tumours by this route.Introduction
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Figure 4. Doxorubicin structure.
Doxorubicin has two major functional groups: a primary amine group in a sugar moiety and a
primary hydroxyl group of -C=OCH2OH group in the aliphatic chain ring.
The drug may be bound in the nanoparticle in form of a solid solution or dispersion, or may be
adsorbed to the surface of the nanoparticles, depending on the physical characteristics of both,
polymer and drug. If a physical binding to the nanoparticles is not possible incorporation of the
drug into the nanoparticles can be achieved by two methods: by incorporation of the drug
during nanoparticle production or by absorption after nanoparticle formation by incubation in
the  drug  solution.  In  our  study,  doxorubicin-poly(butyl  cyanoacrylate)  nanoparticles  were
produced by incorporating the doxorubicin at the time of  production, this resulted in a polymer
matrix with doxorubicin partly incorporated into the matrix but also adsorbed onto the surface.
1.6 The use of nanoparticles for drug delivery in glioma tumour
cells
1.6.1 Overcome the multidrug resistance in tumour cells
A decrease of drug accumulation in cells may be the result of both, a decrease in drug
influx and an increase in drug efflux. Since most of the chemotherapeutic drugs enter cells by
way of passive diffusion through the cell membrane, changes in drug influx can be linked toIntroduction
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changes in cell membrane structure. This could cause either changes in drug trafficking through
the cell membrane or influence on signalling pathways controlling apoptosis.
Drug efflux from resistant cell is considered to be the main cellular method of decreasing drug
accumulation in cells. Drug efflux is mediated by the activity of P-gp, transporters of the MRP
family, and some others proteins.
MDR cells overexpress P-glycoprotein, resulting in a higher degree of resistance to anticancer
agents. For instance, cancer cells frequently acquire MDR against doxorubicin. Treatment of
these P-gp expression tumours with anticancer drugs in combination with a chemosensitizing
agent (modulator agent) that can modulate the P-gp activity has been shown to improve the
efficacy  of  the  anticancer  drug  and  reverse  the  P-gp  mediated  MDR  phenotype.  The
modulators function by blocking the transporter-mediated drug efflux and thereby cause in
combination with an anticancer drug the drug accumulation within the cells, leading to the
death of the tumour cell.
As  many  tumour  cells  are  resistant  to  doxorubicin,  the  incorporation  of  this  drug  into
biodegradable poly(alkyl cyanoacrylate) nanoparticles has been investigated in resistant cells
(59, 60). Interestingly, it has been also shown that the association of doxorubicin with poly(alkyl
cyanoacrylate) nanoparticles also reversed the resistance to doxorubicin in a large number of
multidrug-resistant cell lines (11). The nanoparticle-associated doxorubicin accumulated within
the cells and appeared to avoid the P-gp-dependent-efflux. This reversal was only seen with
poly(alkyl  cyanoacrylate)  nanoparticles  and  was  not  observed  to  be  due  to  nanoparticle
endocytosis. Rather, the formation of a complex between positively charged doxorubicin and
negatively charged polymer degradation products seemed to favour the diffusion across the
membrane (10). However, the exact mechanism, by which doxorubicin-nanoparticles bypasses
the multidrug-resistance mediated by P-gp still remains unclear.
The  broad-spectrum  of  P-gp  substrates,  containing  different  structural  and  chemical
characteristics,  makes  it  very  difficult  to  elucidate  which  mechanism  is  used  to  pump
doxorubicin out of the cell. Furthermore, it is also unclear at which level P-gp is acting. The
drug-substrate can penetrate into the cell through the membrane and then once it reaches the
cytoplasm it will be pumped out by P-gp-mediated transport. But it could also be at membrane
level where the P-gp acts, extruding the drug situated in the transmembrane.
Due to this, the identification of methods for circumventing these drug efflux transport systems
has  attracted  significant  attention  as  potential  ways  to  improve  the  internalization  and
accumulation of therapeutic agents in the organism.Introduction
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In accordance with all of above mentioned findings, we were interested in optimizing the
internalization of doxorubicin into the tumour cells and employed poly(butyl cyanoacrylate)
nanoparticles to enhance the doxorubicin transport across the membrane as well as the used
of a P-gp inhibitor that could inhibit the pump efflux of doxorubicin out of the cells.
Recent  studies  suggested  that  Pluronic®  block  copolymers  (poly(ethylene  oxide)-block-
poly(propylene oxide)-block-poly(ethylene oxide) are potent non-ionic surfactant inhibitors of P-
gp in cells (9-13). In MDR cancer cells, Pluronic® block copolymers enhanced the accumulation
of drugs and increased their cytotoxicity effects (9, 10).
1.6.2 Poloxamer 185 (Pluronic® P85), a P-gp Inhibitor
Initial work using Pluronic® block copolymers was focused on their ability to incorporate
drug molecules and transport the drugs within the body. The discovery of the effect of these
compounds  on  multiple  drug  resistance  (MDR)  of  tumours  was  later  recognized  and  had
important implications for drug delivery.
One important factor for the activity in MDR cancer cells is the effect of the concentration and
composition of Pluronic®  block  copolymers  (24).  Pluronic®  block  copolymers  have  been
shown to increase doxorubicin absorption in P-gp expressing cancer tumour cell lines (10). It
has been demonstrated that Pluronic® block polymers hypersensitize MDR cells resulting in an
increase of the cytotoxicity activity of anticancer drugs with respect to these cells by 2 to 3
orders of magnitude (9). Due to this fact, the drug accumulation within the cells is increased,
which enhances the drug activity.
Pluronic®  block  copolymers  or  amphiphilic  block  copolymers  (ABCs)  have  been  used  in
pharmaceutical applications ranging from sustained release to gene delivery applications. The
use of ABCs for delivery of therapeutic agents was developed from their exclusive chemical
structure consisting of a hydrophilic block, which is chemically bound to a hydrophobic block.
The ethylene oxide (EO), hydrophilic block, and the propylene oxide (PO), hydrophobic block,
arrange in a basic A-B-A structure: EOx  -POy -EOx. Due to their amphiphilic nature, Pluronic®
block copolymers are able to self-assemble into micelles in aqueous solutions at or above CMC
(critical micelle concentration). The pluronic molecules assemble into dense micelles with PO
blocks (lipophilic) remaining inside the micelles and EO blocks (hydrophilic) on the outside ofIntroduction
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micelle  structure.  Upon  micellezation,  the  hydrophobic  core  regions  (PO  blocks)  serve  as
reservoirs for hydrophobic drugs, which may be loaded by chemical, physical or electrostatics
means, depending on the specific functionalities of the core-forming block and the solubilization
properties.  The  presence  of  a  hydrophilic  polymeric  on  the  surface  of  polymeric  micelles
induces steric repulsive forces and stabilizes the micellar surface. This prevents the adsorption
of proteins to the delivery system. As a result, polymeric micelles may efficiently escape the
uptake of RES. The extent of steric stabilization is dependent on the hydrophilic block (EO) and
its density on the colloidal particles. In fact, copolymers were originally used as stabilizers for
colloidal suspension as emulsions, liposomes, and nanoparticles. The adsorption of block
copolymers on the surface of those carriers was found to affect the pharmacokinetics and
biological fate of the delivery system, leading to a long circulation and accumulation in sites with
leaky capillaries. (61). Variations in the number of hydrophilic EO units and lipophilic PO units
result in copolymers with different molecular mass and distinct hydrophilic-lipophilic balance
(HLB). Copolymers with short hydrophilic poly-EO block and/or long lipophilic poly-PO block are
highly lipophilic and are characterized by a relatively low CMC and low HLB. In contrast,
copolymers with a long hydrophilic poly-EO block and/or a short lipophilic poly-PO block are
hydrophilic  and  are  characterized  by  a  relatively  high  CMC  and  high  HLB.  Pluronic®
compounds such as poloxamer 185 are intermediate in their lipophilicity and have CMC and
HLB values that fall between the two extremes identified above.
The effect of Pluronic® on the P-gp efflux system is mediated by unimers. Batrakova et al. (18)
showed that an increase in the accumulation of Rhodamine-123 (Rho-123), a P-gp substrate,
and hypersensitization effects induced by Pluronic® block copolymers in MDR cancer cells
occur at Pluronic® concentrations below the CMC. This means that both effects are caused by
the block copolymer single chains, termed unimers. As a result, Rho123 accumulation and
doxorubicin toxicity increase with increasing concentrations of Pluronic®  until  the  CMC  is
reached and the unimer concentrations level off. Previous work demonstrated that the exposure
of cells to Pluronic® decreases intracellular levels of the P-gp substrates (19). This can be one
reason for the effect of Pluronic® copolymers on the function of energy dependent transporters
such as P-gp. Batrakova et al. (25) demonstrated that the effect of poloxamer 185 (P85) on the
decrease of ATP available in BBMEC monolayer was not due to leakage of intracellular ATP out
of  the  cells  but  rather  a  result  of  inhibition  of  cellular  metabolism.  The  mitochondria  are
responsible for carrying out much of the metabolic activities in the cell and might be a potential
site of action for this compound. A confocal microscopy study showed that P85 is transported
inside  the  cells  and  spreads  throughout  the  cell,  where  it  may  interact  with  intracellular
organelles  including  the  mitochondria  (25).  A  study  from  Rapoport  (26)  showed  that  twoIntroduction
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Pluronic® copolymers, P85 and P105, reduce the activity of the electron transport chain in the
mitochondria. This study indicates that these molecules are transported inside the cells and
reach the mitochondria (27, 28). In addition, Batrakova et al. suggested that P85 significantly
enhanced the brain penetration of a P-gp substrate, digoxin, in wild-type mice expressing
functional P-gp, resulting in brain/plasma levels of digoxin similar to those observed in P-gp-
deficient knock-out mice (29).
Pluronic®  block  copolymers  have  a  tri-block  structure  containing  a  central  hydrophobic
poly(propylene  oxide)  segment  flanked  by  two  hydrophilic  poly(ethylene  oxide)  segments.
Hydrophobic poly(propylene oxide) can incorporate itself into the lipid membrane and induce
changes in membrane structure (30). It is also hypothesized that Pluronic® copolymers can
increase the microviscosity of the membrane, resulting in a decrease of the fluidity.
Accumulation  studies  using  radioactively  labelled  poloxamer  185  indicate  that  the  single
molecule chains of the block copolymer are more efficiently taken up in the cells than the P85
chains incorporated within the micelles (25). This is probably due to the smaller size of the
unimers compared with the micelles as well as the ability of unimers to bind with the cell
membranes.  Cellular  accumulation  of  poloxamer  185  at  micellar  concentrations  of  block
copolymers  is  likely  a  result  of  the  combination  of  both,  unimer  and  micellar  transport
processes. Poloxamer 185 induces drastic changes in the microviscosity of the cell membranes
in BBMCE. Similar changes were observed in cancer cells treated by other Pluronic® block
copolymers (36). These changes can be attributed to the alterations in the structure of the lipid
bilayer because of the adsorption of the block copolymer molecules on the membrane.
At  concentrations  below  CMC,  poloxamer  185  apparently  inhibits  P-gp  function,  thereby
reducing drug efflux out of the brain microvessel endothelial cells. At concentrations above the
CMC,  this  surfactant  appears  to  increase  vesicular  transport  of  the  drug  into  the  brain
microvessels (32). Above the CMC, this block copolymer is able to form micelles. Under these
conditions the Rho-123 and doxorubicin levels reveal a tendency for first levelling off and then
decreasing. At high concentrations of Pluronic®, Rho-123 is incorporated into micelles and is
transported  through  a  vesicular  route,  resulting  in  different  accumulation  kinetics  (21).
Furthermore, exposure of the cells to the micelles induces removal of the drug from the cells
through an unclear mechanism.Perspective of the work
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2  Perspective of the work
The objective of this study is to expand the capacity of doxorubicin of treating several types
of  tumours  for  the  use  in  brain  tumour  therapy.  As  already  known,  tumour  cells  display
resistance  to  doxorubicin  because  of  drug  resistance  phenomena.  Doxorubicin  is  a  P-gp
substrate and therefore presently is not used for the treatment of brain tumours.
The employment of poly(butyl cyanoacrylate) nanoparticles have previously been shown to
facilitate the distribution of doxorubicin into the brain (76). Moreover, these particles very
significantly increased the survival time of rats with intracranial transplanted glioblastoma 101/8
(72). Poly(butyl cyanoacrylate) nanoparticles were produced in order to carry doxorubicin and to
enhance its internalization through the cellular membrane of the tumor cells thus overcoming
the resistance presented in these cells.
Based on previous results, the modification of the surface characteristics of the nanoparticles
has been demonstrated to be of great importance for reaching the target tissue and/or cell. The
different chemical nature of the coating surfactants enables different surfactant properties, and
hence it was decided to compare the effect of several surfactants, polysorbate 80, poloxamer
188, and poloxamine 908 on the drug uptake.
In the present study, the capacity of these three surfactants on the transport of doxorubicin
through  the  cellular  membranes  of  the  glioma  tumour  cells  as  well  their  influence  on  the
cytotoxicity on the glioma cell lines after incubation with free doxorubicin and after adsorption to
nanoparticles was studied. The sensitivity of either doxorubicin alone or doxorubicin formulated
in  poly(buty  cyanoacrylate)  nanoparticles  towards  glioma  cells  was  analysed  using  three
cytotoxicity detection assays, the MTT, the LDH, and the ATP tests.
An in vitro evaluation was carried out using different glioma cell lines, the GS9L, the RG-2, and
the F-98 cell lines, to investigate cell-line-specific differences in the degrees of resistance to
chemotherapy. In addition, the P-gp expression was analysed in the three cell lines.
Since, the drug resistance mechanism of the three cell lines, GS9L, F-98, and RG-2 cell lines
also involves the P-gp expression, poloxamer 185, a known P-gp inhibitor, was employed as an
additional new coating surfactant.Materials and Methods
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3  Materials and Methods
3.1 Preparation of poly(butyl cyanoacrylate) nanoparticles
3.1.1 Reagents and Laboratory equipment
Reagents
n-Butyl-2-cyanoacrylate Sicomet
 6000)
Poloxamer 188 (Pluronic F-68) Sigma Steinheim, Germany
poloxamin 908 (Tetronic
 908) Sigma Steinheim, Germany
Polysorbate 80 (Tween
 80) ICI Chemicals Essen, Germany
Poloxamer 185 (Pluronic
 P85) BASF, Ludwighafen, Germany
Dextran 70000 Sigma Steinheim, Germany).
Doxorubicin  Sicor, Rho, Italy
Mannitol  Merck, Darmstadt, Germany
0.01N HCl  Merck, Darmstadt, Germany
0.1N NaOH  Merck, Darmstadt, Germany
1N NaOH Merck, Darmstadt, Germany
2N NaOH Merck, Darmstadt, Germany
0.9 % (w/v) NaCl Merck, Darmstadt, Germany
Dichloromethane Merck, Darmstadt, Germany
n-Butanol, p.A.       Merck, Darmstadt, Germany
n-Pentanol, p.A.       Fluka, Seelze, Germany
Sodiumsulfate Merck, Darmstadt, Germany
Laboratory equipment
GC-System:
GC: HP5890 Series II        Hewlett-Packard, Bad Homburg, Germany
Integrator: HP3396 A
Column:
Fused Silica Capillary Column, Permabon-FFAP-DF-0,1, 25 m x 0,25 mm ID
Machery-Nagel, Düren, Germany
Centrifuge-Filter (Ultrafree MC, 100,000 NMWL)    Millipore, Eschborn, Germany
HPLC-System:
Mobile phase  :
70% Water          Milli-Q- Millipore, Eschborn, Germany
30% Acetonitril          Merck, Damstadt, Germany
+ 0,1 % Trifluoracetic acid          Fluka, Seelze, Germany
Interface: D-7000          Merck-Hitachi, Darmstadt, Germany
Pump: D-7120          Merck-Hitachi, Darmstadt, Germany
Column: LiChroCart 250.-4 with LiChrospher 100 RP-18 (5µm)
Autosampler: D-7200
Detector: D-7420, UV/VIS; D-7480, FluoreszenzMaterials and Methods
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Lyovac GT2 freeze dryer Leybold AG, Köln, Germany
G2 glass filter Schott, Mainz, Germany
Magnetic stirrer RCT basic                             KA Labortechnik, Staufen, Germany
Ultrasonicbath Sonorex RK31                        Bandelin electronic GmbH & Co. KG., Berlin
Ependorf Centrifuge 5415 D                          Eppendorf AG, Hamburg, Germany
Analyse Balance Sartorius CP 224S                Sartorius, Göttinegen, Germany
Malvern Zetasizer 3000 Has                          Malvern, Wores, UK
Laminar-Flow sterilbench                               Heraeus, Hanau, Germany
3.1.2 Nanoparticles production procedure
3.1.2.1  Poly(butyl cyanoacrylate) nanoparticles (PBCA-NP)
Unloaded  polybutylcyanoacrylate  nanoparticles  (unloaded-PBCA  nanoparticles)
nanoparticles  were  obtained  by  anionic  polymerization  at  pH  below  3.  1%  (w/v)
butylcyanoacrylate monomer was added to a 1% solution of dextran 70.000 in 0.01N HCl (pH
2) under magnetic stirring for 4h. After 4 h the nanoparticle suspension is neutralized with NaOH
(0.1 or 1N) and filtered through a sintered G2 glass filter (pore size of 90-150µm) to remove
larger. The nanoparticles were lyophilized adding 3% mannitol as cryoprotector and using a
Lyovac GT2 free dryer. The nanoparticles were stored in 2 ml vials at 4°C.
The unloaded-PBCA and Dox-PBCA-NP preparation were carried out under aseptic conditions.
To achieve this, all material and components used for nanoparticle preparation were autoclaved
and the solutions were filtered through 0.22 µM filter membranes. The polymerization was
carried out under a laminar flow sterile bench.
The nanoparticles were resuspended in 0.9 % (w/v) NaCl solution prior use.
3.1.2.2  Doxorubicin-loaded-poly(butyl cyanoacrylate) nanoparticles (Dox-PBCA-NP)
Doxorubicin-polybutylcyanoacrylate  nanoparticles  (Dox-PBCA  nanoparticles)  were
prepared using the same procedure of polymerization but with only 2.5 h polymerization time
instead of 4 h. 30 min after the start of polymerization a doxorubicin solution (25mg/ml in 0.01N
HCl) was added to the polymerization medium. The final concentration of doxorubicin was 0.25
% (w/v). After 2.5 h the nanoparticle suspension is neutralized with NaOH (0.1 or 1N) and
filtered through a sintered G2 glass filter The nanoparticles were lyophilized in vials of 1-2 mlMaterials and Methods
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using a Lyovac GT2 freeze dryer and a solution of 3% Mannitol was used as cryoprotector. The
nanoparticles were resuspended in 0.9 % (w/v) NaCl solution prior to use.
3.1.2.3  Coating Procedure
The poly(butyl cyanoacrylate) nanoparticles were coated with polysorbate 80 (Tween®
80),  poloxamer  188  (Pluronic F-68), poloxamin 908 (Tetronic  908),  or  poloxamer  185
(Pluronic® P85). These surfactants are always used in solution at a 1 % concentration. An
amount  of  100  µl  of  10  %  surfactant  solution  was  added  to  900  µl  of  the  nanoparticle
suspension or in the case of the doxorubicin control to 900 µl doxorubicin solution. After this
these nanoparticles were stirred for 30 min and then used immediately for cell incubation.
3.1.3 Characterisation of Dox-loaded- and unloaded-PBCA-NP
3.1.3.1  Size determination
The  size  of  the  nanoparticles  was  determined  by  photon-correlation  spectroscopy
(PCS), i. e. the hydrodynamic diameter.
The size of the nanoparticles was found to be 190 ± 30 nm
3.1.3.2  Yield polymerization
The polymerisation yield was measured by gas chromatography (GC) as described
(103). Briefly, nanoparticle suspension was hydrolysed with 2 N NaOH shaking overnight at
room temperature. 50 µl of this solution were mixed with 50 µl of internal standard (pentanol
approx. 0.5 %) and diluted with 900 µl of Milli-Q water. 500 µl of the diluited solution were
extracted with 1000 µl of methylene chloride. The methylene chloride was dried with water-free
sodium  sulphate  and  1µl  of  the  sample  was  injected  into  the  GC  system.  The  following
instrument parameters and conditions were used:Materials and Methods
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Instrument Parameter
Injector: split / splitless HP 19251 – 60540, 250°C
Detector: FID, 250°C
Oven-Temperature: Gradient, 45°C (3 min)  10°C 1/min  130°C (4 min)
Gas
Aux gas: Helium (Qualität 5.0)
Column flow: 1,0 ml / min
Split flow: 10,0 ml /min
Septum flow: 1,1 ml / min
Column + Aux: 35 ml / min
Column + Aux + Air: 430 ml / min
Column + Hydrogen + Aux: 65 ml / min
Column head pressure: 94 kPa
3.1.3.3  Drug loading
To  determinate  the  doxorubicin  entrapment  efficiency,  lyophilized  Dox-poly(butyl
cyanoacrylate) nanoparticles were resuspended in water and the particles were separated from
the  solvent  by  centrifugation.  100  µl  of  nanoparticle  suspension  were  transferred  to
microcentrifuge filters and centrifuged at 16000 g for 20 min. Concentration of free doxorubicin
dissolved in supernatant was determined by HPLC. The filtered solution containing the free
doxorubicin  was  injected  after  dilution  by  1:100  to  the  HPLC  system  and  the  amount  of
doxorubicin was calculated.
The  chromatographic  separation  was  performed  on  a  250x4  mm  column  packed  with
LiChrospher® 100 RP-18(5µm). The mobile phase was phosphate buffer (pH 4.2; 0,01 M)
acetonitrile (60:40). The detector was set to 250 nm. The following analysis parameters were
usedMaterials and Methods
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HPLC-System:
Liquid chromatgraph: D-7000   Merck-Hitachi
Packing: LiChrospher® 100 RP-18 (5µm)   Merck, Germany
Column: LiChroCART® 250-4 HPLC-Cartridge Merck, Germany
Guard column: LiChroCART® 4-4
Injection volume: 20 µl
Flow rate: 0,8 ml / min.
Detection:
- Absorption = 250 nm
- Fluorescence = _ex 480 nm, _emm 560 nm
Temperature: ambient
Mobile phase: mixture phosphate buffer (pH 1,4; 0,01M) - acetonitrile (60:40)
3.2 Cell Culture
3.2.1 Cell line and Growth Medium
GS-9L
GS-9L-Medium
500 ml DMEM Gibco, Pasley, UK
50 ml Fetal calf serum, inactive Gibco, Pasley, UK
10 ml L-Glutamin [200 nM] Gibco, Pasley, UK
5 ml Penicillin/Streptomycin [10.000 µg/ml] Gibco, Pasley, UK
5 ml MEM non-essential amino acids (NNAA) Invitrogen, Karlsruhe
This is a cell line of non-human/non-primate origin. Its morphology corresponds to glia cells and
its specie is rat. The GS-9L rat glioma cell line was derived from N-nitrosomethylurea-induced
tumour.  The  rat  glioma  GS9L  cell  line  was  cultured  as  a  monolayer  in  DMEM  medium
supplemented with 2% L-glutamine, 1% penicillin/streptomycin, 1% non-essential amino acids
and 10% foetal bovine serum under cell culture conditions (37°C, 5% CO2). GS-9L is an
adherent cell lineGS-9L cell line was supplied by ECCC
RG-2
RG-2 Medium
500 ml DMEM                                                   Gibco, Pasley, UK
50 ml Fetal calf serum, inactive                 Gibco, Pasley, UK
10 ml L-Glutamin [200 nM]                             Gibco, Pasley, UK
5 ml Penicillin/Streptomycin [10.000 µg/ml]      Gibco, Pasley, UKMaterials and Methods
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The rat glioma cell line RG-2 was produced by inoculation with a single dose of N-ethyl-N-
nitrosourea in a pregnant CD Fischer rat. The biological characteristics of this tumour closely
resemble those of human glioblastome. The cells come from brain tissue and its morphology is
glia. The cells were cultured as monolayer, growing as adhederent monolayer in DMEM medium
supplemented with 2% L-glutamine, 1% penicillin/streptomycin, and 10% foetal calf serum. RG-
2 cell line was supplied by ATCC.
F-98
F-98-Medium
500 ml DMEM Gibco, Pasley, UK
50 ml Fetal calf serum, inactive Gibco, Pasley, UK
10 ml L-Glutamin [200 nM] Gibco, Pasley, UK
5 ml Penicillin/Streptomycin [10.000 µg/ml] Gibco, Pasley, UK
The tumour was produced by inoculation with a single dose of N-ethyl-N-nitrosourea. The
biological characteristics of this tumour closely resemble those of human glioblastome. The cells
come from brain tissue and its morphology is glia. The rat glioma cell line F-98 was cultured as
monolayer,  growing  as  adherent  monolayer  in  DMEM  medium  supplemented  with  2%  L-
glutamine, 1% penicillin/streptomycin, and 10% foetal calf serum. F-98 cell line was supplied by
the Institute of Virology (Frankfurt am Main, Germany).
Caco-2
Caco-2-Medium
500 ml DMEM Gibco, Pasley, UK
50 ml Fetal calf serum, inactive Gibco, Pasley, UK
10 ml L-Glutamin [200 nM] Gibco, Pasley, UK
5 ml Penicillin/Streptomycin [10.000 µg/ml] Gibco, Pasley, UK
5 ml MEM non-essential amino acids (NNAA) Invitrogen, Karlsruhe
The Caco-2 intestine cell line consists of human colonocyte derived adenocarcinoma cells. To
apical to basolateral uptake transport, highly differentiated Caco-2 cells express variable levels
of several efflux pump proteins depending on cell source and culture conditions.
The cells were grown in DMEM (Dubelcco´s Modified Eagle´s Medium) supplemented with 10%
fetal  bovine  serum,  0.1mM  nonessential  amino  acids,  100  U/ml  penicillin,  and  0.1mg/ml
streptomycin. Caco-2 cell line was supplied by ATCC.Materials and Methods
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3.2.2 Cell Culture Reagents and Materials
Trypsin/EDTA  Gibco, Pasley, Scottland
Cytoperm Incubator Heraeus, Hanau, Germany
Cell culture flasks (50ml, 75ml, 250ml) Greiner, Frickenhausen, Germany
Glasstic® Slide 10 with Grids Hycor, Penicuik, UK.
Microtiter 12-, 24-, 96-well plate Greiner, Frickenhausen, Germany
Multichannel pipette  Costar, Wiesbaden, Germany
Sterile Pipettes (5 ml, 10 ml, 25ml) Sarstedt, Nürnbrecht, Germany
Plastic tubes Falcon® (15ml, 50ml) Greiner, Frickenhausen, Germany
Laminar Flow sterile bench  Heraeus, Hanau. Germany
Cytoperm Incubator Heraeus, Hanau. Germany
3.3 Cytotoxic detection assays
3.3.1 Materials
Trypsin/EDTA              Gibco, Pasley, Scottland
Cytoperm Incubator                                        Heraeus, Hanau, Germany
Glasstic® Slide 10 with Grids  Hycor, Penicuik, UK
Microtiter 12-, 24-, 96-well plate  Greiner, Frickenhausen, Germany
Multichannel pipette     Costar, Wiesbaden, Germany
Sterile Pipettes (5 ml, 10 ml, 25ml)  Sarstedt, Nürnbrecht, Germany
Plastic tubes Falcon
® (15ml, 50ml)  Greiner, Frickenhausen, Germany
3-(4,5-dimethylthiazol-2-yl)-2,5-diphynyl-tetrazoliumbromid (MTT) Sigma, Steinheim
LDH test (Cyto kit)                                          Roche, Basel, Switzerlanf
HS Vialight, BioWhitaker                                Cambrex, UK
      NRR (Nucleotid Releasing Agent)
     AMR (ATP Monitoring Agent)
Photometer Spectra Max 340                          MWG Biotech, Ebersberg, Germany
Luminometer MicroLumat LB 96P                  Berthold, Bad Wildbad, Germany
Triton 100-X                                                   Merck, Darmstadt, Germany
To measure the ability of the cell to survive, and to continue proliferate, different proliferation or
cytotoxicity assays were carried out.
For testing, the cells are trypsined and seeded at 1*10
5 cells/ml in 96-well plate and were
incubated overnight to allow them to adhere to the bottom. The cells are counted using trypan
blue by hemocytometer technique. The cells were incubated with the different formulations for
24h. The medium is removed, at the end of the drug exposure and the cells were washed toMaterials and Methods
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eliminate any rest of samples and further incubated with 200 µl of fresh medium for 24 h in the
absence of the drug in order to determine an irreversible effect of doxorubicin on cell survival
and not only the direct effect of the drug on a metabolic pathway or process. Thus, we are
certain to measure the mitochondrial activity or enzyme activity of the cells, which are able to
proliferate after long exposure to doxorubicin. For the three tests the positive control are
untreated cells and negative control are cells treated with 1% NaN3.
3.3.2 MTT-Test
This assay is based on the measurement of the mitochondrial activity of viable cells by
the reduction of the tetrazolium salt MTT (3-(4,5-dimethyathiazol-2-yl)-2,5-diphenyl tetrazolium
bromide) to a blue product formazan. Formazan is insoluble in water and must be solubilized in
isopropanol/HCl. A stock solution of 5 mg/ml was prepared in PBS and diluted 1:10 before use
(1 mg/ml). The MTT solution was filtered through a 0.22 µM filter membrane. The cells were
plated into 96-well microtiter plates and 50 µl of sterile filtered of 1 mg/ml MTT solution was
added to each well. After 2 – 3 h the medium is removed and the plate was protected from the
light  and  incubated  for  10  min  to  allow  a  better  solubilization  of  formazan  crystal.  The
absorbance of formazan dye was recorded at 540 nm with an ELISA plate reader. Since the
absorbance directly correlated with the number of viable cells, the viability was calculated from
the absorption. The wells, which contained medium, MTT but no cells, were used as blank in
the plates reader.
3.3.3 LDH-Test
The cells were plated into 96-well microtiter plates for this assay. The LDH assay
(Roche) analyses the activity of the cytoplasma enzyme lactate deshydrogenase, LDH, released
from the cytosol of damaged cellular membrane into the supernatant. The LDH activity was
determined using a commercial kit, containing a salt (tetrazolium salt INT) and an enzyme
(catalyst). The reduction of nicotinamide (NAD+) to NADH/H+ in presence of lactate and LDH,
and  posterior  reduction  of  tetrazolium  salt  INT  in  presence  of  NADH/H+  and  catalyst
(diaphorase) results in a red product, formazan, which could be measured at 590 nm using a
spectrophotometer. The absorbance then was correlated with the number of viable cells.
The cells, which were able to survive after drug exposure, were lysed with 0.1% TritonX-100,
and the released LDH started the reaction that was measured.Materials and Methods
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3.3.4 ATP-Test (HS Vialight, BioWhitaker, Cambrex)
The cells were platted on a 96 well microtiter plate.
The ATP assay (Cambrex) is based on the measurement of ATP present in all metabolically
active cells by using the enzyme luciferase that catalyses the formation of light from ATP and
luciferin. The light produced by the previous reaction is recorded in relative light units (RLU) by a
luminometer, and corresponds with the number of viable cells.
3.4 Detection of P-glycoprotein (Western Blot)
3.4.1 Material and Reagents
Trypsin/EDTA Gibco, Pasley, Scottland
Cytoperm Incubator Heraeus, Hanau, Germany
Sterile Pipettes (5 ml, 10 ml, 25ml) Sarstedt, Nürnbrecht, Germany
Plastic tubes Falcon
® (15ml, 50ml) Greiner, Frickenhausen, Germany
Cell culture flasks (50ml, 75ml, 250ml) Greiner, Frickenhausen, Germany
0,2 µm Nitrocellulose membrane Schleicher x Schnell
HP chemiluminescence film Hyperfilm
TM Amershams BS, Uppsala, Sweden.
Bio-Rad Protein assay (Bio-Rad) München, Germany.
C219 (mdr1 polyclonal antibody) Calbiochem, San Diego, USA.
Mouse monoclonal anti-rabbit Ig peroxidase Dianova, Hamburg, Germany
ECL Plus western Blotting Detection Reagents Amersham BS, Uppsala, Sweden
Lysis Mix
    Lysis Buffer: 10 mM KCl; 1,5 mM MgCl2; !0 MM Tris-HCl (pH 7,4)
    PMSFS
    Protese inhibitors Roche, Basel, Switzerland
Branson  Ultraschall-Desintegrator  Sonifier  250 G.  Heinemann,  Schwäbisch
Gmünd, Germany
3.4.2 Procedure
Membrane samples were prepared from Caco-2, GS-9L, F-98, and Rg-2 cells. The cells
were washed with PBS and detached by trysinized and collected by centrifugation at 3000 g forMaterials and Methods
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5 min. The pellets were incubated with lysis buffer and put them on ice for 10 min. Cells were
shortly 3 times sonificated, avoiding the formation of foam and keeping the samples on ice.
After that the lysates were centrifuged 500 g for 10 min to remove nuclei and debris. Protein
concentration was determined using the Bradford assay. Equal amounts of protein were loaded
for each sample (40µg). Samples were run on a 7,5% SDS-polyacrylamide gel at 100 volt for 90
min, and the proteins were transferred to a nitrocellulose membrane at 12 volt for 30 min. The
membrane was blocked with 5% non-fat dry milk for 1 h then incubated with 1:1000 dilution of
anti-P-glycoprotein  C219  (mdr1  polyclonal  antibody)  overnight,  followed  by  three  times
washings, and incubation with a 1:10000 dilution of a secondary antibody, mouse monoclonal
anti-rabbit Ig peroxidase conjugated for 60 min, followed by further three times washings.
Inmunoreactive proteins were subsequently detected using the ECL Plus western Blotting
Detection Reagents and exposing the membrane to high performance cheminoluminescence
film Hyperfilm
TM.
3.4.3 Protein determination by Bradford
The concentration of protein in the cellular lyses was detected by a commercial detection
assays,  Bio-Rad-Assay,  Bio-Rad.  The  detection  consists  in  a  unspecific  interaction  of
Coomassie-Blue with the aromatic amino acids (Bradford, 1976). 2 µl of the cellular lyses added
in 800 µl of the reagent and incubated for 5-10 min on ice. The measurement was done in a
BioRad Spectrophotometer at 595 nm.
3.5 Cellular accumulation of doxorubicin
3.5.1 Flow Cytometer (FACS Analysis)
Flow cytometry is the measurement of characteristics of single cells (cyto) suspended in a
flowing saline stream. A focussed beam of laser light hits the moving cell and light is scattered
in all directions. Detectors placed forward of the intersection point or side-on (with respect to
the laser beam) receive the pulses of scattered light and they are converted into a form suitable
for computer analysis and interpretation. The total amount of forward scattered light detected is
closely correlated with cell size, whereas the amount of side scattered light can indicate nuclearMaterials and Methods
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shape or cellular granularity. The results were analysed by the CellQuest Pro programm.
3.5.1.1  Material
FACSCalibur Becton-Dickenson, Heidelberg, Germany
CellQuestPro Becton-Dickenson, Heidelberg, Germany
Trypsin/EDTA Gibco, Pasley, Scottland
Cytoperm Incubator Heraeus, Hanau, Germany
24-well plates Greiner, Frickenhausen, Germany
FACS tubes Gibco, Pasley, Scottland
Steril Pipetten (5 ml, 10 ml, 25ml) Sarstedt, Nürnbrecht, Germany
Plastic tubes Falcon
® (15ml, 50ml)   Greiner, Frickenhausen, Germany
PBS-Buffer pH 7,4 Biochrom, Berlin, Germany
3.5.1.2  Procedure
For this study we used FACS (Fluorescence Activated Cell Sorter) analysis. The cells
were split at 10
5 cell/ml in 24 well plate overnight to allow them to adhere on the bottom of the
plate. Next day the incubation with the different samples is started. The cells are incubated for 4
h with the different formulations. After the incubation time the cells are washed, trypsinized, and
collected in 1 ml of medium in FACS tubes. The cell suspension is centrifugated at 14000 g for
10 min. Then the medium is discarded and the pellets resuspended in 500 µl FACS-PBS (PBS
with 3 % FCS) by vortex and further centrifuged. The cells were washed three times before
measurement by FACS.
3.5.2 Confocal Laser Scanning Microscopy (CLSM)
3.5.2.1  Material and Reagents
Concavalin A Alexa Fluor 594 conjugate  Molecular Probes, Eugene, Oregon,Materials and Methods
32
USA
Leica DM IRBE  Leica, Heidelberg, Germany
Leica Confocal Software  Leica, Heidelberg, Germany
8-chambre slides  Nunc, Wiesbaden, Germany
3.5.2.2  Procedure
In order to study the uptake of doxorubicin by the different cell lines, confocal laser
scanning microscopy (CLSM) was used. The intracellular localization of doxorubicin in the
different cell lines is analysed by CLSM since fluorescence images can be made using the
autofluorescence of doxorubicin. A krypton-argon laser line (488nm) was used for excitation of
doxorubicin, and a long pass filter (550nm) was used for detection of the emitted light.
For this assay the GS9L, F-98, RG-2 and Caco-2 cell lines were seeded in 8-chambre slides,
and incubated overnight to allow them to adhere on the bottom. At the next day, the incubation
with the doxorubicin formulations was made over 6 h. This is the time that it was established to
see a maximal accumulation of doxorubicin within the cells, assuring still a viable state of the
cells. The coating of the nanoparticles was just done before the start of the incubation period.
The control was always untreated cells. Then, the cells were carefully washed three times with
PBS, to avoid detaching the cells. The cellular membrane was stained with the dye Cy5 ConA,
adding 100µl of Cy5 from a stock solution and waiting 2 min for each well. The dye then is
discarded and three times with PBS washed, leaving a small amount of PBS within the well.
3.5.3 Cellular membrane study
3.5.3.1  Material and Reagents
Concavalin A Alexa Fluor 594 conjugate  Molecular Probes, Eugene, USA
Leica DM IRBE  Leica, Heidelberg, Germany
Leica Confocal Software  Leica, Heidelberg, Germany
8-chambre slides Nunc, Wiesbaden, Germany
3.5.3.2  ProcedureMaterials and Methods
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The  GS9L  cells  were  seeded  in  8-chambre  slides,  and  incubated  overnight.  The
surfactants solutions prepared and 50 µl of each solution added to each well containing 450 µl
medium.  The  concentrations  were  prepared  10x  concentrated  to  obtain  the  desired  final
concentration.
The cells were incubated for 24 h with the surfactant solutions. At the end of the treatment, the
cells are washed with PBS three times and the membrane stained with 100 µl Cy5 solution for 2
min. The cells washed three times with PBS, leaving a small volume of PBS within the wells.Results
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4  Results
4.1 Preparation and characterization of poly(butyl cyanoacrylate)
nanoparticles (PBCA-NP) and Dox-poly(butyl cyanoacrylate)
nanoparticles (Dox-PBCA-NP)
4.1.1 Preparation procedure
The nanoparticles used in this study were prepared by an emulsion polymerization
process. The polymerization mechanism was an anionic process, initiated by bases such as
OH
– resulting from the dissociation of water.
Figure 6  A. Alkyl cyanoacrylate molecule. B. Anionic emulsion polymerization process of alkyl
CyanoacrylatesResults
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The  polymerization  procedure  is  carried  out  by  the  addition  of  the  monomer,  butyl
cyanoacrylate, into the polymerization medium, which consists of an aqueous acidic solution of
0.01 N HCl (pH 2), and the stabilizer dextran 70000 under constant stirring.
The molecular weight of the polymer depends on the pH. In the presence of high concentration
of  H
+ the polymerization termination is rapid, leading to small molecular weights. At lower
concentrations of H
+ the termination rate is reduced and, consequently, the resulting molecular
weights increase. At low molecular weights, the growing particles can be very soft and prone to
agglomeration. For this reason, stabilizers have a significant influence on the particle size and
the molecular weight (52, 53). The influence of the stabilizer was found to also be very important
for product yield (77,78). The yield was assessed by gas chromatography (GC), described
thoroughly in the Material and Methods section and was found to be 60 %.
Other  factors  contributing  to  the  particle  size  of  the  nanoparticles  include  monomer
concentration and stirring speed. Because the solubility of the cyanoacrylate is exceeded at
concentrations above 0.05%, monomer droplets are formed and the system has to be stirred
constantly. The particle size increases slightly with increasing stirring speed (52). This increase is
caused by the higher kinetic energy of the system at higher agitation forces. The increased
kinetic energy level of the system enables some oligomers, small semisolid particles, and even
larger particles to overcome the interfacial energy barrier surrounding the particles, leading the
coalescence with other particles (53, 54). The preparation of nanoparticles in the present study
took place at 1% butyl cyanoacrylate and 500 rpm speed.
4.1.2 Size of the nanoparticles
The  particle  size  determines  the  surface  area  available  for  contact  with  the  cell
membrane  and  has  an  influence  on  the  mechanism  by  which  the  nanoparticles  will  be
internalized into these cells.
There  are  several  factors,  which  can  determine  the  size.  Different  pH  values  of  the
polymerization medium influence on the particle size differently: a particle size minimum exits at
around pH 2, whereas the polydispersity falls with increasing pH.
The stabilizers also have a significant influence on the uniformity of particles size (77,78). The
particles size was measured by Photon Correlation Spectroscopy (PCS). The particle size of ourResults
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nanoparticles ranged from 190 nm to 200 nm and the distribution was monomodal.
4.1.3 Zeta potential
PBCA NP and coated PBCA NP showed negative zeta-potentials in distilled water, a
general phenomenon of theoretically uncharged polymeric particle. Adsorption of doxorubicin
on the surface modifies the charge of nanoparticles towards a positive value, caused by the
positive charge of this drug.
4.1.4 Loading of Dox-poly(butyl cyanoacrylate) nanoparticles
The load of the Dox-PBCA-NP was assessed in the supernadant of the nanoparticles
suspension after centrigugation. Relative drug loading (% of total amount) was calculated by
subtraction of free drug in the supernatant from the total amount in the vials and was found to
be 70 % of loading.
4.2 The Growth Inhibition of Glioma Cells after Doxorubicin and
Dox-PBCA-NP incubation. Cytotoxicity Assays
Drug targeting systems, such as PBCA-NP, have to face three challenges, one is the
avoidance of the macrophages of the mononuclear macrophages system (MPS), the second is
to direct the carriers to the desired site of action, and the third is to yield a high delivery of the
drug to the targeted cells. Previous works already demonstrated quite successful avoidance of
the MPS by the poly(butyl cyanoacrylate) nanoparticles (83) and, therefore, in many cases an
enhanced transport of the drug to the target tissue (76, 82). Moreover, it was found that binding
of doxorubicin to nanoparticles increased the efficacy against glioma tumours (72). Responsible
for  this  achievement,  was  a  selective  alteration  of  the  surface  characteristics  of  these
nanoparticles that represent the key factors to determine the organ distribution of these carriers.
Therefore,  one  of  the  objectives  of  this  work  was  the  analysis  of  the  influence  of  suchResults
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modification on the action and transport of the doxorubicin into the targeted tumour cells, the
glioma cells. For this purpose, the doxorubicin-poly(butyl cyanoacrylate) nanoparticles were
coated with three non-ionic surfactants.
The present in vitro study involves the evaluation of the chemosensitivity of three rat glioma cell
lines  towards:  (1)  doxorubicin  in  solution,  (2)  doxorubicin-poly(butyl  cyanoacrylate)
nanoparticles, and (3) coated-doxorubicin-poly(butyl cyanoacrylate) nanoparticles (coated-Dox-
PBCA NP).
In order to determine the effect of the nanoparticles formulations on the cells as well as the
sensitivity of the glioma cells to doxorubicin, the cytotoxic effect of doxorubicin was evaluated
by its inhibitory effect on the cell proliferation. Widely employed, cell viability tests or proliferation
tests were used to determine the potential carcinogenicity or cytotoxicity of the anticancer drug.
The  existing  well  described  proliferate  assays  to  evaluate  the  cellular  sensitivity  to
chemotherapeutics drugs are employed according to the authors preferences because of their
ease of use, optimal condition, measurement requirement, etc. In the present in vitro study the
cytotoxicity of different formulations was evaluated using three assays measuring different
parameters. The assays were the MTT, the LDH, and the ATP assays.
In the MTT assay, a tetrazolium (MTT) salt is added to the media and upon internalizing into the
cells, is reduced to a blue product by the mitochondria dehydrogenase into the mitochondria.
The absorbance is recorded and the extend of the viability was defined as the relative reduction
of the absorbance, which is directly correlated with the amount of viable cells in relation to the
cell control (= 100 %).
The LDH is a cytosplamic enzyme, which after cellular membrane damage is released from the
cytosol  into  the  extracellular  media.  This  enzyme  catalyzes  the  reduction  of  lactate  to  a
formazan (a red product), which absorbance is recorded. For this purpose in our experiments,
the cells were subjected to doxorubicin either in free form or in the nanoparticles formulations
for 24 h. The surviving still viable cells were then cultivated with doxorubicin-free medium for
another 24 h. After this time these remaining cells were lysed with a 1 % Triton X 100 solution,
and released LDH by this lysis was determined, indicating the percentage of cells that survived
the  doxorubicin  treatment.  The  decrease  in  the  formazan  absorbance  in  relation  to  the
untreated cell control (= 100 %) corresponded to a decrease in the LDH activity, and therefore
was a decrease of the expression in the cellular viability caused by the doxorubicin action.
In the ATP assays, the amount of ATP contained in the cells is used to give the conversion from
luciferin to oxiluciferin with the corresponding emittance of light, which is recorded. Thus, the
decrease of the amount of ATP, due to a decrease in the cell number of living cells indicates a
viability decrease.Results
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4.2.1 Effect of doxorubicin solution on the GS-9L, RG-2, and F-98 glioma
cell lines
At first, the sensitivity of the glioma cell lines, GS9L, RG-2, and F-98 towards free
doxorubicin was analysed in order to identify cell-line-specific differences in the degrees of
resistances to doxorubicin.
The cytotoxic effect of doxorubicin in solution was tested at concentrations ranging from 0.1
µg/ml to 5 µg/ml doxorubicin. The cells were incubated for 24 h in the presence of different
concentrations of doxorubicin and keeping them a further 24 h in the absence of the drug. The
survival rate of the cells was calculated and results are expressed as:
Percent of survival = 100 x (number of treated cells surviving) / (number of untreated cells)
The mean percentages of cell survival (viability) and the corresponding standard deviations were
calculated. The curves of viability percentages represented in Figure 7.
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Figure 7. Viability of the GS-9L, RG-2, and F-98 glioma cell lines after exposure of doxorubicin
concentrations, according the three assays.
As shown in figure 7, the cytotoxic effect of doxorubicin measured by LDH, or ATP MTT test
was concentration-dependent in all cell lines.  The decrease of viability was most pronounced at
low doxorubicin concentrations below 1 µg/ml.  At higher concentrations, the viability of RG-2
and F98 cells did not change significantly up to the highest concentration of 5 µg/ml.  Only in
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the GS-9L cell line, a further marked decrease in cell viability depending on the assay was
observable, which was most considerable in the LDH test and statistically insignificant in the
ATP test.   Moreover, the GS-9L cell line appeared to be the least sensitive to the drug:   The
viability of this cell line at doxorubicin concentrations between 1 µg/ml and 5 µg/ml was ~ 50 -
30%, whereas the viability of the F-98 and the RG-2 cells was below 20 % in most cases.  At
the same time, it has to be mentioned that the cytotoxicity induced by doxorubicin measured by
the three tests was different between the cell lines, this difference being most pronounced for
the GS-9L cells.  The concentration capable of reducing the cell proliferation by 50 %, IC50, was
calculated. As expected, different values of IC50 observed between the three cell lines is caused
by a different response of the cell lines to doxorubicin, resulting in a varied degree of resistance
presented by the cells, cell lines-specific resistance differences. However, when we compare
the values obtained for one cell line using the three assays, a discrepancy is observed, which is
clearer once the IC50, is calculated for each cell line, depicted in Table 1. The difference in the
calculated IC50 values was most pronounced for the F-98 cell line in the ATP test
The cytotoxicity of free doxorubicin was not increased by the presence of either surfactant (data
not  shown).  Only  the  effect  of  polysorbate  80  occasionally,  at  low  concentrations  of
doxorubicin, showed a slightly increase in the cytotoxicity of free doxorubicin.   The effects of
poloxamer 188 and poloxamine 908 were negligible.
Table 1. IC50 values for the GS9L, RG-2, and F-98 cell lines, according to the MTT, LDH, and
ATP assays
Cell line (IC50 values µg/ml)
Assay GS9L RG-2 F-98
MTT 1.4 0.2 0.4
LDH 3.9 0.6 1
ATP 0.6 0.6 0.01
The different values of IC50 observed between the three assays show variability in the results
and it is therefore not easy to establish to what degree the different rat glioma cell lines are
chemosensitive towards the doxorubicin solution. Nonetheless, the IC50 for GS-9L is always the
highest independent of the assay used, meaning that the GS-9L cells present the lowest growth
inhibition, and therefore the highest resistance towards doxorubicin. RG-2 has the lowest
resistance in LDH and MTT test whereas F-98 shows less resistance than RG-2 in ATP test. InResults
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the MTT test, no significant difference between RG-2 and F-98 appeared. The growth-inhibiting
effect of doxorubicin is variable, depending on the cell line. Therefore, the different responses to
doxorubicin  can  be  accounted  for  by  a  relationship  of  doxorubicin  with  a  variety  of  the
resistances presented by the cells.
4.2.2 Effect of unloaded-PBCA-NP on the viability of the GS-9L, RG-2, and
F-98 glioma cell lines
The absence of cytotoxicity of the unloaded nanoparticles is an important requirement
for their usefulness as a carrier system for doxorubicin.
To prove the absence of cytotoxicity of unloaded-PBCA-NP, the cell lines were incubated with
the unloaded-PBCA-NP in a range of concentrations between 0 µg/ml and 25 µg/ml of polymer
with the objective to establish a maximum-non-toxic concentration of unloaded-PBCA-NP.
From  the  results  obtained  in  this  experiment,  it  was established  that  the  maximum
concentration, which did not produce any toxic effect in any of the all cell lines was 15 µg/ml of
polymer.  Consequently,  this  concentration  was  used  as  a  reference  for  all  following
experiments.
The effect of the coating of the unloaded nanoparticles on the cell proliferation was also
assessed. The surfactants used were polysorbate 80 (Ps 80), poloxamer 188 (PF68), and
poloxamine 908 (Tetronic®). The coating of the nanoparticles was done just before incubation
with 1 % solution of each surfactant. Then, the cells were incubated with a concentration of 15
µg/ml of uncoated- and coated-, unloaded-PBCA-NP for 24 h. Figure 8 depicts the viability
values for the three cell lines according to the MTT test, the LDH test, and the ATP test.Results
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C.
Figure 8. Cellular survival after 24 h incubation with unloaded-PBCA-NP, according to MTT,
LDH, andATP assays on (A.) GS-9L, (B.) F-98, (C.) RG-2 cell lines.
As  shown  in  figure  8,  no  significant  decrease  of  the  cell  number  was  observed  and  the
nanoparticles coated with the different surfactants did not exhibit a significant cytotoxic effect
with the exception of polysorbate 80 (Ps80-PBCA-NP) in the LDH test after incubation of the
RG-2 cells, where the viability decreased considerably.
4.2.3 Effect of Dox-PBCA-NP on the viability of the GS-9L, RG-2, and F-98
glioma cell lines compared to doxorubicin solution
Once proved that the unloaded-PBCA-NPs were non-toxic for the cells, the question
arose if the cytotoxic activity of doxorubicin against the glioma cells could be enhanced by
means of nanoparticles and if the use of surfactants as surface coatings improves the drug
delivery into the glioma cells. For this reason, the nanoparticles were loaded with doxorubicin
and coated as described in Material and Methods section. The effect produced by the Dox-
PBCA-NP (uncoated and coated) was compared with the effect produced by doxorubicin in
solution at equivalent doxorubicin concentrations.
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The loaded doxorubicin-nanoparticles were coated at a 1% concentration with the previous
surfactants as used to coat the empty NPs in the earlier tests (polysorbate 80, poloxamer 188,
and  poloxamine  908).  The  effect  of  doxorubicin  in  solution  and  doxorubicin  bound  to
nanoparticles was assessed using the MTT test and LDH test only, because the ATP was not
available any more. The evaluation of the effect of doxorubicin solution and Dox-PBCA-NP
(uncoated- and coated-) was carried out at different concentrations of doxorubicin ranging from
0.1 µM to 5 µM. The maximum concentration of polymer used was 15 µg/ml for all experiments.
The cells were incubated for 24 h with the samples, at which time the medium was changed
and the cells were incubated for a further 24 h in the absence of the drug. The cells capable of
proliferating after the drug exposure were quantified by measuring their mitochondrial activity
using the MTT assay, and the LDH activity by the LDH assay.
4.2.3.1  MTT results for doxorubicin solution and Dox-PBCA-NP
In the Figure 9, the MTT data again shows a concentration-dependent decrease in all
three  cell  lines.  This  decrease,  as  seen  in  doxorubicin  solutions  (Figure  7),  was  most
pronounced at low doxorubicin concentrations up to 1 µM and in most cases did not change
up to a doxorubicin concentration of 5 µM. However, a different response of the cell lines
towards doxorubicin formulations was observed. In general, doxorubicin in solution displayed a
lower  cytotoxicty  towards  the  cells  as  compared  to  Dox-PBCA-NP,  throughout  at  low
concentrations. The F-98 cell line especially demonstrates this effect and shows a very low
viability at high concentrations. For the RG-2 cells a drastic drop in viability to very low levels
was observed at 1µM doxorubicin.Results
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Figure 9. Viability of GS-9L, F-98, and RG-2 according to MTT assay after 24 hours of incubation
with different concentrations of doxorubicin formulations.
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As already shown in Figure 7, again the GS-9L cell line appeared to be the least sensitive to
doxorubicin, since the cell viability of GS-9L cells was much higher than in the F-98 and RG-2
cell lines at doxorubicin concentrations between 1 µM and 5 µM. In the latter cell lines (F-98 and
RG-2) the viability was considerably below 20 % in most cases.
However, in general the effect of coating of the nanoparticles with the surfactants on the
increase of efficacy of doxorubicin although statistically significant in some cases was practically
not important. Only in the case of GS-9L cells, poloxamine 908 and poloxamer 188 coating
showed a visible decrease in the viability, which was more pronounced at low concentrations.
Additionally the viability of the RG-2 and F-98 cell lines decreased significantly after Ps 80-Dox-
PBCA-NP exposure.
According to the MTT assay, it is obvious that the GS-9L cell line shows a higher resistance to
every formulation of doxorubicin than the RG-2 and F-98 cell lines, and the RG-2 cell line seems
to be more sensitive than the F-98 cell line for every formulation.
4.2.3.2   LDH assay results for doxorubicin solution and Dox-PBCA-NP
The  LDH  assay  data  show  a  slight  concentration-dependent  cytotoxic  effect,  for
doxorubicin in solution as well as for the nanoparticulate formulations (Figure 10). Again the GS-
9L  cell  line  was,  even  at  high  concentrations,  the  most  resistant  towards  the  action  of
doxorubicin. The RG-2 cells were the most sensitive towards doxorubicin, as well as to the
other formulations.
In  the  GS-9L  cells,  only  Ps  80-Dox-PBCA-NP  caused  a  higher  decrease  in  viability  than
doxorubicin  in  solution  with  a  dose  dependent  effect  leading  to  zero  viability  at  5  µM
doxorubicin. The rest of coatings did not improve the doxorubicin activity in relation to uncoated
nanoparticles and doxorubicin alone.
In the F-98 cell line the three coatings had a significant effect on the viability of the cells even
more at lower concentrations, with a marked dose dependent effect leading to zero viability for
Ps80-Dox-PBCA-NP.Results
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Figure 10. Viability  of  GS-9L,  F-98,  and  RG-2  according  to  the  LDH  assay  after  24  hours
incubation with different concentrations of several doxorubicin formulations.
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However, the uncoated nanoparticles and doxorubicin solution do not display such a decrease,
resulting in a similar effect for both formulations.
On  the  other  hand,  RG-2  presented  a  marked  viability  decrease  with  an  increase  in  the
concentration of doxorubicin for all formulations tested, that was even more pronounced at low
concentrations of doxorubicin.
At higher concentrations, polysorbate 80 (Ps 80) also was the most effective surfactant in the
LDH assay in all cell lines.
The difference between Ps80-Dox-PBCA-NP and doxorubicin in solution was clear in all three
cell lines showing a higher viability decrease after treatment with Ps80-Dox-PBCA-NP than with
free doxorubicin. A marked influence of poloxamine 908 and poloxamer 188 was observed in F-
98  cell  line  and  a  somewhat  lesser  influence  was  visible  in  RG-2  cell  lines  compared  to
uncoated Dox-PBCA-NP (Fig. 10).
Throughout the viability values obtained by the LDH assay were lower than those obtained
using the MTT assay under the same conditions. There is a concordance in the two assays
showing the GS-9L as the most resistant cell line.
4.3 Intracellular  Accumulation  of  Doxorubicin  and  P-gp
expression in the Glioma Cell Lines
As stated above, doxorubicin showed a different growth inhibition effect on the three cell
lines. To explain this different sensitivity to doxorubicin observed in the three cell lines, which
was largely independent of the formulation used, the uptake of doxorubicin into the cells was
analysed.  This  intracellular  accumulation  of  doxorubicin  was  measured  by  flow  cytometer
(FACS), exploiting the fluorescence capacity of doxorubicin. The cells were incubated with 1 µM
doxorubicin  solution  for  4  h  and  the  mean  fluorescence  of  the  cells  was  recorded,
corresponding with the uptake of doxorubicin into the cells. As seen in Figure 11, the amount of
doxorubicin accumulated after 4 h differed in the three cell lines.Results
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Figure 11. Intracellular accumulation of doxorubicin in GS-9L, RG-2, and F-98 cell lines after 4 h
incubation, measured by flow cytometer analysis.
As expected, the uptake of doxorubicin by the GS-9L cells was significantly lower, as compared
to the uptake by the RG-2 and F-98 cells. The difference in the uptake between the RG-2 and
F-98 was not significant. Therefore, the low sensitivity of the GS-9L cells seen in the cytotoxic
assays corresponds to a lower accumulation of doxorubicin into the cells.
One of the possible reasons of low accumulation in tumour cells, such as glioma cells, may be
multidrug resistance (93, 94, 95). The accumulation of doxorubicin into the cells depends on its
transport across the cellular membrane. The transport of doxorubicin into resistant cells is
governed by the multidrug resistance (MDR). Given that one of the prime transporters mediating
multidrug resistance is the P-glycoprotein (P-gp) and that doxorubicin is a P-gp substrate (91,
92), we analysed the expression of this efflux pump protein in the different cell lines. The
expression of this transmembrane transport protein was assessed by Western blot technique
(Figure 12). The Caco-2 cell line was used as a positive P-gp expressing cell line.
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Figure 12. Western blot analysis of P-gp in GS-9L, RG-2, and F-98 rat glioma cell lines. Caco-2 cell
line  was  used  as  positive  P-gp  expressing  cell  line.  P-gp  was  detected  using  the
monoclonal P-gp antibody C219 (1:1000 dilution).
The Western blot shows that the  different cell lines express  the  P-gp protein  to  different
degrees. The first band corresponds to the positive P-gp expressing control cell line, Caco-2.
The second band, GS-9L cell line shows a stronger expression of this efflux pump, showing a
more pronounced protein expression than the RG-2 and F-98 cell lines.
The expression of P-gp normally corresponds with drug resistance. Therefore, the different
degrees of expression of P-gp in the cell lines are probably responsible for the variation of the
responses to doxorubicin in the three cell lines. This means that this transmembrane protein is
responsible for the efflux transport of doxorubicin, decreasing the doxorubicin accumulation and
therefore increasing the resistance to the cytostatic drug. The low level of accumulation of
doxorubicin in the GS-9L cell line showed by FACS analysis corresponded to a high expression
level of P-gp, which pumps doxorubicin out of the cells, resulting in a decrease of its activity on
the cells, corroborating the results observed by the cytotoxic assays in the GS-9L cell line.
In contrast, the increased sensitivity of RG-2 and F-98 towards doxorubicin is caused by an
increased  intracellular  accumulation  of  doxorubicin  due  to  the  fact  that  the  lower  P-gp
expression level in these cells results in less extend of the efflux transport of doxorubicin. This
further backs the fact that the expression of P-gp on the RG-2 and F-98 cell surfaces is lower
than on GS-9L.
Caco-2 GS-9L RG-2 F-98
Tubulin
P-gp
190 kD
170 kD
50 kDResults
51
4.4 Uptake and Localization of Doxorubicin into Glioma Cells
The conclusions deducted from the previous cytotoxic assay results led us to presume
that  Dox-PBCA-NP,  even  at  low  concentrations  of  doxorubicin,  enhances  the  uptake  of
doxorubicin into the tumour cells. Consequently their cytotoxic activity against tumour cells
should be higher than doxorubicin in solution. The different responses shown for each cell line
using the same range of concentrations of doxorubicin and the same assay conditions would
be justified by specific resistances at the cellular level presented by the tumour cells. As said
previously, the P-gp expression in the cellular membrane of the glioma cells seems to be the
responsible for the different sensitivity towards doxorubicin.
Drugs such as doxorubicin appear to enter the cell by passive diffusion through the lipid bilayer
(96), resulting in sensitive cells towards doxorubicin. However with resistant cells, upon entering
doxorubicin into the cells, the drug binds to the P-gp protein and is pumped out of the cell (85,
86). To circumvent this multidrug resistance at the cellular level many authors have proposed
the use of competitive inhibitors such as the calcium channel blocker, verapamil (86). One
problem faced by the clinical use of verapamil is the serious adverse effects of this compound.
Another strategy suggested for delivery of anticancer drugs, with the aim of overcoming the
resistance phenomena, is the association of the drug with nanoparticles (86, 87). Couvreur et al.
carried out studies where doxorubicin was encapsulated in various types of nanoparticles (6,
59) and the sensitivity of resistant cells to the doxorubicin-loaded-nanoparticles was then
evaluated by measuring the cytotoxic effect produced by increasing the concentration of the
doxorubicin-loaded-nanoparticles. Resistant cells treated with doxorubicin-loaded poly(alkyl
cyanoacrylate) (PACA) nanoparticles showed a much higher sensitivity than to the free drug (6,
59, 84, 87, 88).
As expected, by our previous cytotoxicity results, the doxorubicin either in solution or absorbed
on the PBCA nanoparticles showed different growth-inhibiting effects on the three glioma cell
lines  at  equivalent  concentrations  of  doxorubicin.  This  fact  was  due  to  the  resistance
phenomena, above described, presented by the glioma cells towards cytotoxic drugs, such as
doxorubicin. The results also clearly revealed that such resistance was presented in a different
degree by each cell line due to the specific resistance at the cellular level, represented by the
expression of the P-glycoprotein (see figure 12). Thus, all said above led us to evaluate the
capacity of doxorubicin to overcome the P-gp mediated efflux once doxorubicin was formulated
as nanoparticles and/or with a P-gp inhibitor.
Given that the spectrum of P-gp substrates and P-gp inhibitors is very wide, the P-gpResults
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inhibitor for our analysis was chosen taking as reference the Batrakova´s studies where it was
demonstrated that poly(ethylene oxide)-poly(propylene oxide) block copolymers (Poloxamers)
are potent inhibitors of the P-gp drug efflux system (7, 8, 9, 65). Formulation of P-gp-dependent
drugs with poloxamer 185 (Pluronic
® P85) resulted in significant increases in their transport to
P-gp expressing cells. Experimental studies have been demonstrated to show that Pluronic
®
block-copolymers sensitize MDR cells, resulting in an increase in the cytotoxic activity of the
anthracyclines and others drugs.
In  this  study,  poloxamer  185  was  formulated  with  doxorubicin  solution  and  Dox-PBCA
nanoparticles. In the case of Dox-PBCA nanoparticles it was used to coat the nanoparticle
surface and in the case of doxorubicin solution it was just mixed with a poloxamer 185 solution.
The aim of this analysis was to use the P-gp inhibition capacity of poloxamer 185 to improve the
transport of doxorubicin into the cells, avoiding its efflux out of the cells by the P-gp and
increasing its intracellular accumulation.
It was also observed in the cytotoxic assay data that polysorbate 80 used as a coating was
responsible for a marked effect on the viability of all the cell lines. Moreover some studies
proposed that polysorbate 80 also possesses a P-gp inhibition activity (79, 80). For this reason
it was decided to analyse the two surfactant, poloxamer 185 and polysorbate 80, comparing
their effect on the P-gp activity and, therefore, their effect on the doxorubicin uptake.
4.4.1  Uptake of doxorubicin into GS9L cell line
For these experiments a concentration of 1 µM of doxorubicin was used, either in Dox-
PBCA nanoparticles or in doxorubicin solution. FACS analysis and CLSM analysis were carried
out to evaluate this P-gp inhibition on the GS-9L glioma cell line.
4.4.1.1   FACS Analysis
Using FACS analysis, it was possible to determine to which grade doxorubicin entered
into  the  different  cell  lines.  Doxorubicin  in  solution  and  Dox-PBCA  nanoparticles  were
formulated with poloxamer 185 and polysorbate 80. Doxorubicin solution was mixed with 1 %
solution of poloxamer 185 and 1 % polysorbate 80, and the Dox-PBCA nanoparticles wereResults
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coated with 1 % poloxamer 185 and 1 % polysorbate 80 solutions. The fluorescence coming
from doxorubicin quantified to the accumulation of doxorubicin into the cells. Figure 13 shows
the percentage of fluorescence measured, which is directly proportional to the amount of cells
that took up doxorubicin.
Figure 13. Fluorescence signal of doxorubicin at 590 nm (λexp = 480 nm) after incubation with the
cells for 4 h.
As can be seen, the maximal fluorescence signal came from the formulations containing the
poloxamer 185, especially in the case of P185-Dox-PBCA-NP where the signal is the highest.
The formulations containing polysorbate 80 as well showed a significant fluorescence signal in
comparison  to  doxorubicin  in  solution  and  uncoated  Dox-PBCA-NP.  Accordingly,  an
improvement of the uptake of doxorubicin by the cells was observed after incubation with both
polysorbate 80 and poloxamer 185, poloxamer 185 showing a greater improvement. It has to
be  mentioned  that  the  doxorubicin  bound  to  uncoated  nanoparticles  showed  a  better
internalization that free doxorubicin.
Therefore, the three nanoparticle formulations yielded a better cell uptake than the simple
solutions of doxorubicin, either alone or in solution with a surfactant in the GS-9L cell line.
Thus, the different drug resistances showed by the three cell lines were responsible for a
variable entry of doxorubicin into the cells. It was demonstrated that this resistance was higher
in cells with higher P-gp expressions (see above results). According to this, the inhibitory effect
of  poloxamer  185  on  the  P-gp  activity  is  visible  on  the  GS9L  P-gp  expressing  cell  line,
enhancing the accumulation of doxorubicin into the cell.
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4.4.1.2  CLSM Analysis
Subsequently, the accumulation of doxorubicin into the cells was visualized by CLSM
assay after 6 h incubation. The same doxorubicin formulations as in the FACS experiment were
used: doxorubicin solution, doxorubicin+1% P185 solution, doxorubicin+1%Ps80 solution, Dox-
PBCA nanoparticles, P185-Dox-PBCA nanoparticles, and Ps80-Dox-PBCA nanoparticles.
In the Figure 14 the confocal microscope show the effect of poloxamer 185 and polysorbate 80
on the uptake and localization of doxorubicin for the GS-9L cell line.
Differences in accumulation of doxorubicin into the cells were clearly observed with respect the
different formulation employed. The microphotographs of the GS-9L glioma cell line show that
doxorubicin in solution scarcely internalizes into the cells, showing the lowest uptake of the drug
after 6 h incubation. However, after incubation with Dox-PBCA nanoparticles, the cells did take
up doxorubicin better than doxorubicin in solution. The presence of polysorbate 80 in the
formulations also showed an improved internalization of doxorubicin but to fewer degrees than
in the presence of poloxamer 185. Therefore, in the presence of poloxamer 185, either as a
solution  or  as  a  coating  of  the nanoparticle surface the uptake of doxorubicin was clearly
increased in comparison to the rest of all of the formulations.
Figure 14. Intracellular localization of doxorubicin in GS-9L cell line by confocal microscopy. Cells
were  exposed  to  various  Dox-PBCA-NP  and  doxorubicin  formulations  for  6  h  and
examined by fluorescent confocal microscopy.Results
55
The intracellular localization on doxorubicin was also markedly different with the employed
formulations. Poloxamer 185 allowed the accumulation of doxorubicin in the nucleus with both,
doxorubicin solution or bound to nanoparticles (Fig. 14). In the case of Ps80-Dox-PBCA-NP the
doxorubicin was localized in certain areas of the cytoplasm, whereas after incubation with
uncoated Dox-PBCA nanoparticles there is a diffused localization of doxorubicin.
4.4.2  Uptake of doxorubicin into RG-2 cell line
4.4.2.1  FACS Analysis
The same FACS experiments were carried out with the RG-2 cell line. As Western blot
analysis demonstrated, we need to take into consideration that the P-gp expression in this cell
line was very low. In the next figure, the intracellular accumulation of doxorubicin after 4 h for
RG-2 cell line is shown.
Figure 15. Fluorescence signal of anthracyclines at 590 nm (λexp = 480 nm) after incubation with
the cells for 4 h.
Contrary to that what was seen in the GS-9L cell line, the RG-2 cell line showed a high
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fluorescence  signal  after  incubation  with  the  doxorubicin  in  solution,  which  was  almost
comparable  to  the  signal  produced  by  Dox-PBCA-NP  and  the  formulations  containing
poloxamer 185. FACS analysis also showed that there was no significant difference between
the uncoated Dox-PBCA-NP and the P185-Dox-PBCA-NP. Dox+Ps80 and Ps80-Dox-PBCA-
NP showed the weakest signals with a slight increase of the fluorescence for the Ps80-Dox-
PBCA-NP.
4.4.2.2  Confocal microscopy analysis
In the figure 16, the intracellular accumulation of doxorubicin after 6 h for RG-2 cell line
is shown. As seen in the confocal microscopy images, an effect of poloxamer 185 on the RG-2
cell line was only slightly detectable because a high internalization was also detectable with
doxorubicin alone. The improvement of the uptake of doxorubicin into the cells using uncoated
Dox-PBCA-NP and P185-Dox-PBCA-NP was very similar, as also shown by FACS analysis.
Doxorubicin  in  solution,  as  well  as  doxorubicin  containing  poloxamer  185,  crosses  the
membrane successfully. On the other hand, the nanoparticles coated with polysorbate 80 and
doxorubicin+Ps80 do not present a large improvement. Nevertheless, the Ps80-Dox-PBCA-NP
facilitates the uptake of doxorubicin compared to the uptake of doxorubicin after incubation with
doxorubicin+Ps80. In addition, the Dox-PBCA-NP formulation seemed to yield a higher uptake
of doxorubicin than doxorubicin alone or doxorubicin+Ps80. The intracellular localization of
doxorubicin lead to accumulation in the nucleus poloxamer 185  treatment, whereas Ps80-Dox-
PBCA-NP showed marked perinuclear localization of doxorubicin.Results
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Figure 16. Intracellular localization of doxorubicin in RG-2 cell line by confocal microscopy. Cells
were exposed to various Dox-PBCA-NP and Doxorubicin formulations for 6 h and
examined by fluorescent confocal microscopy.
With this cell line, an enhancement in the uptake of doxorubicin by the use of PBCA-NP was
not observed. Moreover, the poloxamer 185 effect in the RG-2 cell line was not as pronounced
as in the GS-9L cell line, where the amount of doxorubicin taken up was significantly lower than
that of the poloxamer 185 formulation, almost by 50 %. Polysobarte 80 had a stronger effect on
the RG-2 cell line than on the GS-9L cel line.
4.4.3  Uptake of doxorubicin into the F-98 cell line
4.4.3.1  FACS Analysis
The FACS data for F-98 cell line are depicted in Figure 17. There were not many
differences in the accumulation of doxorubicin between the several formulations and poloxamer
185. No significant increase of the intracellular doxorubicin was observed in any formulations.Results
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Figure 17. Fluorescence signal of doxorubicin at 590 nm (λexp = 480 nm) after incubation with the
cells for 4 h.
Therefore, it can be concluded that, as with RG-2 cell line, in the F-98 cell line doxorubicin alone
could cross the membrane very efficiently as FACS analysis shows. Moreover, PBCA-NP did
not show a significant enhancement of the doxorubicin transport and poloxamer 185 showed a
poor effect on the improvement of the accumulation of doxorubicin into the cells. No significant
difference was seen in the presence or in the absence of poloxamer 185. One reason for this is
that the P-gp expression in the F-98 cell line was very low. The effect of this was that the
doxorubicin was not subjected to P-gp-mediated transport due to the lack of P-gp on the
surface of the cells. Only in the case of nanoparticles coated with poloxamer 185 showed the
highest signal.
4.4.3.2   Confocal microscopy analysis
In the case of F-98 cell line, after 6 h incubation with the different formulations, the
internalization of doxorubicin in the cells increased for all formulations, as shown in the Figure
18.  The  accumulation  of  doxorubicin  into  the  cells  appeared  to  be  much  lower,  almost
insignificant with the Ps80-Dox-PBCA-NP and with doxorubicin+Ps80 as compared to the rest
of the formulations.
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The rest of the formulations showed an important accumulation of the drug independently of the
presence of either poloxamer 185 or PBCA-NP. The F-98 cells took up doxorubicin to a high
extent even after incubation with the doxorubicin in solution alone. These results were very
similar to those with the RG-2 cell line.
Figure 18. Intracellular localization of doxorubicin in F-98 cell line by confocal microscopy. Cells
were  exposed  to  various  Dox-PBCA-NP  and  doxorubicin  formulations  for  6  h  and
examined by fluorescent confocal microscopy.
The confocal microscopy analysis shows similar results to those acquired by FACS analysis.
Only one discrepancy to the FACS results was found. The decreased uptake of doxorubicin
after incubation with polysorbate 80 formulations shown by CLSM was not apparent by the
FACS analysis.Results
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4.4.4 Uptake of doxorubicin into Caco-2 cell line
The Caco-2 cell line is frequently used as a model of the human intestinal mucosa
representing a biological barrier model and it is a useful in vitro system for studying the P-gp
function (87). Thus, this cell line also was employed in the present study because of its high
expression of the P-gp protein.
4.4.4.1  FACS Analysis
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Figure 19. Fluorescence signal of doxorubicin at 590 nm (λexp = 480 nm) after incubation
with the cells for 4 h.
The figure 19 shows the cellular fluorescence after treatment with the different doxorubicin
formulations.  Unexpectedly,  the  effect  of  poloxamer  185  to  improve  the  intracellular
accumulation of doxorubicin was negligible. Doxorubicin, with either P185 or Ps80 did not
enhance  its  cell  accumulation.  A  significant  increase  was  observed  after  binding  to
nanoparticles and the P185-Dox-PBCA-NP yielded the highest uptake.Results
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4.4.4.2  Confocal microscopy analysis
The Caco-2 cells were split in an 8-chamber slide and incubated for 2-3 days allowing
them to grow to a confluent monolayer. After a minimum confluence of 80 % was reached the
experiment was started.
Figure 20. Intracellular localization of doxorubicin in Caco-2 cell line analysed by confocal
microscopy.  The  cells  were  exposed  to  various  Dox-PBCA-NP  and  doxorubicin
formulations for 6 h and examined by fluorescence confocal microscopy.
The intracellular accumulation of doxorubicin in the Caco-2 was increased in the presence of
PBCA  nanoparticles  formulations,  which  was  even  more  pronounced  in  the  presence  of
poloxamer 185 and polysorbate 80. However, it has to be mentioned that in the case of
doxorubicin+Ps80 and Ps80-PBCA-NP the dye of the cellular membrane was not clearly visible,
therefore the exact localization of doxorubicin cannot be assured. As expected, doxorubicin in
solution  led  to  the  lowest  accumulation  in  the  Caco-2  cells.  Only  poloxamer  185  and
polysorbate 80 yielded a slight accumulation of doxorubicin in solution.Results
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In the following figure the different uptake of doxorubicin in the four cell lines is represented.
Figure 21. Cellular fluorescence after the treatment of doxorubicin formulations in the GS-9L,
Caco-2, F-98 and RG-2 cell lines
The Caco-2 and the resistant GS-9L cells showed the lowest uptake of doxorubicin, which was
increased only when polysorbate 80 or poloxamer 185 were present, being more efficient
poloxamer  185  than  polysorbate  80.  In  both  cell  lines,  the  nanoparticles  enhanced  the
doxorubicin internalization. In the case of the doxorubicin sensitive cell lines, F-98 and RG-2, the
F-98 cells showed higher accumulation of doxorubicin than RG-2 cells, which was largely
independent on the formulation used. However, the presence of polysorbate 80 in the RG-2
cells led to a reduced intracellular accumulation of doxorubicin, whereas poloxamer 185 did not
alter or improve the doxorubicin uptake by the cells in comparison to doxorubicin alone.
In many cases the presence of poloxamer 185 also clearly provoke a nuclear accumulation of
doxorubicin,  whereas  after  treatment  with  polysorbate  80  formulations,  the  doxorubicin  is
accumulated in certain locations in the cytoplasms.
0
10
20
30
40
50
60
70
80
90
100
1µM Dox 
Dox+Ps80
Dox+P85
Dox-Np
Ps80-Dox-Np
P85-Dox-Np
%
 
F
l
u
o
r
e
s
c
e
n
c
e
GS-9L RG-2 F-98 Caco-2Results
63
4.5 Study of the effect of poloxamer 185 and polysorbate 80 on
the integrity of the cellular membrane
In the literature poloxamer 185 and polysorbate 80 surfactants are both well-described as
P-gp inhibitors (8, 9, 65, 79, 80). However, in our previous experiments, it was observed that
the uptake of doxorubicin was increased in the presence of poloxamer 185 in cells with higher
P-gp expression level whereas polysorbate  80  even  led  to  a  reduction  in  the  intracellular
accumulation of doxorubicin in doxorubicin sensitive-cell lines RG-2 and F-98.
The non-ionic surfactant polysorbate 80 has been shown to increase the permeability of certain
transport markers in Caco-2 cells as well as improving the permeation of proteins susceptible to
P-gp-mediated efflux (66, 67). Yamazaki et al. (68) demonstrated that polysorbate 80 enhanced
the cellular accumulation of an epipodophyllotoxin derivate susceptible to P-gp-mediated efflux,
and this was attributed to an increased influx of the drug rather than an inhibition of P-gp-
mediated efflux. Poloxamer (Pluronics®) copolymers have also been shown to enhance the
diffusion  of  compounds  such  as  doxorubicin  across  model  lipid  bilayers  (69).  These
investigations  suggest  that  surfactant  interactions  with  membranes  leading  to  increased
membrane permeability may play an important role in enhancing the transmembrane diffusion of
a P-gp substrate and its intracellular accumulation, independently of the inhibitory effects of
these surfactants on P-gp. However in the previous FACS data and confocal microscopy
images shown, the accumulation of doxorubicin was enhanced in almost all cases due to the
presence of poloxamer 185 and not to the same extend by polysorbate 80. Given that both
surfactants are P-gp inhibitors, this means that the P-gp inhibition activity of both surfactants
differs with the different properties of poloxamer 185 and polysorbate 80 for the uptake of
doxorubicin in the P-gp expressing cell lines. Therefore, the different mechanism by which both
surfactants inhibit P-gp activity could be explained by different effects of poloxamer 185 and
polysorbate 80 on the uptake of doxorubicin by the cells.
Consequently, we focused on the effects of both surfactants on the permeability of the cellular
membrane of the GS9L cell lines possessing the highest P-gp expression. The effects of both
surfactants  on  cell  permeability  were  assessed  after  incubation  with  poloxamer  185  and
polysorbate 80. For this experiment, the cells was exposed to different concentrations of bothResults
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poloxamer 185 and polysorbate for 24h, then the membrane was stained and analysed by
confocal microscopy (see Figure 22).
Figure 22. Integrity of membrane cellular of GS-9L cell line after incubation for 24 h with different
concentrations of poloxamer 185.
The GS-9L cells were incubated with several concentrations of poloxamer 185 ranging from
0.001 % to 1 %. After 24 h of incubation, the surfactant solutions were removed. The cells were
washed,  the  cellular  membrane  stained,  and  the  cells  were  observed  under  the  confocal
microscopy.
The same procedure was carried out for polysorbate 80. The GS9L cells were incubated with
several concentrations of polysorbate 80, ranging from 0.001 % to 1 % surfactant solution.
After 24 h of incubation, the surfactant solutions were removed. The cells were washed and the
cellular membrane stained, which was observed under the confocal microscopy.
In Figure 22 and 23 the Cy5-dyed cellular membranes of the GS-9L cell line are shown. The
Figure 22 figure shows to the cellular membrane after incubation with poloxamer 185 solutions.
It was clearly observed that no significant change of the membrane occurred in the range of
concentrations used.Results
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Figure 23. Integrity of membrane cellular of GS-9L cell line after incubation for 24 h with different
concentrations of polysorbate 80.
As  shown  the  Figure  23,  some  modification  of  the  membrane  was  detected  at  0.01  %
concentration of polysorbate 80. At up to 0.1 % concentration changes of the cellular form were
perfectly evident because of loss of the cellular membrane integrity. The cells swelled changing
into a spheric form, and at 1 % concentration the cells integrity totally vanished, showing
important toxic effects on the cells.
It was therefore concluded that the poloxamer 185 did not display any effect on the cellular
membrane or any toxic effect on the cells at the range of concentration tested. However,
polysorbate 80 showed rather significant changes in the membrane in the same range of
concentrations, and even toxic effects at higher concentrations.Results
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Figure 24. Viability of GS-9L, RG-2, F-98, and Caco-2 cell lines after incubation with different
doxorubicin formulations for 24 h.
When it was noticed that poloxamer 185 considerably improved the uptake of doxorubicin the
question arose if poloxamer 185 also was able to enhance the activity of doxorubicin. The
advantage of a high intracellular accumulation of doxorubicin would be an increase in its activity
as  a  cytotoxic  drug.  To  prove  this,  the  viability  of  the  resistant-GS-9L  cell  line  and  the
doxorubicin sensitive-RG-2 and F-98 cell lines was measured after incubation with poloxamer
185 doxorubicin and polysorbate 80 doxorubicin formulations as well as a doxorubicin solution.
The Caco-2 cell line was used as control cell line. The MTT assay was employed for this
analysis.  The  percentage  of  viable  cells  observed  after  24  h  incubation  with  the  different
samples is represented in Figure 24. The value 100 % corresponds to untreated cells.
The doxorubicin in solution and Dox-PBCA-NP showed a high efficacy against the RG-2 and F-
98 cells and a very low efficacy against the Caco-2 cells and GS-9L showing high viability
values after the treatment with both formulations. However, a considerable decrease in the
viability by the presence of poloxamer 185 and polysorbate 80 occured in both cell lines but to
a lesser degree in the GS-9L cells. This effect is attributable to the high P-gp expression that
both cell lines present on the surface.
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Unexpectedly, the lowest values of viability were found after incubation with polysorbate 80
formulations.  Unexpectldly  because  the  low  uptake  of  doxorubicin  in  the  presence  of
polysorbate 80 shown by CLSM and FACS analysis contradicts the low values of viability with
the identical polysorbate formulations. Moreover, as the viability values indicate the polysorbate
formulations seem to be more effective than the poloxamer 185 formulations, which again
contradict the high entry of doxorubicin in the presence of poloxamer 185 in the formulations
(see above). The apparent effectivity of polysorbate on the viability of the cells was observable in
all cell lines tested. According the MTT assay, all four cell lines also showed lower viability in
presence of polysorbate formulations than in the presence of poloxamer 185 formulations.
4.6 Effects  of  poloxamer  185  and  polysorbate  80  on  the
Rhodamine 123 accumulation
Using Rhodamine 123 (Rho-123), a P-gp substrate, Batrakova et al. demonstrated that
Pluronic®  block  copolymers  could  enhance  Caco-2  cell  accumulation  of  Rho-123  at
concentrations below the CMC of the poloxamers (9). In contrast, at concentrations above
CMC, the poloxamers were found to cause an increased efflux of Rho-123 from Caco-2 cells
(9). Miller et al. (8) were first to report the concentration-dependent effects of poloxamer 185 on
Rhodamine 123 accumulation in BBMCE monolayers.
Therefore, our interest was to analyse this concentration-dependent effect of poloxamer 185
and polysorbate 80 on the accumulation of Rho-123 in GS-9L, RG-2 and F-98 glioma cell lines.
Rho-123 is fluorescent and therefore its cell accumulation also can be measured by flow
cytometer. The concentration-dependent effect of poloxamer 185 and polysorbate 80 also was
compared to the effect of verapamil, a known P-gp substrate.Results
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Figure 25. Rho-123 uptake in GS-9L, F-98, RG-2, and Caco-2 cell lines by FACS analysis. The
effect  of  poloxamer  185  on  the  Rho-123  uptake  was  measured  at  different
concentrations.
The concentration-dependent effect of the different poloxamer 185 concentrations on Rho-123
cellular accumulation is represented in Fig. 25. To estimate the ability of poloxamer to inhibit the
Pgp efflux transport in the cells different poloxamer 185 solutions were produced. As seen in
the figure, one pattern observed in all cell lines is that the Rho-123 cellular accumulation
reaches maximal levels at or near the CMC and decreases at concentrations above CMC.
Indeed, the increases in the Rho-123 uptake at low concentrations of poloxamer 185 from
0.0001 % to 0.01 %, coincide with the inhibition of the P-gp efflux in the BBMEC monolayers in
Batrakova´s experiments (25). A maximal Rho-123 accumulation was observed at 0.01 %
poloxamer 185, which is below the CMC (= 0.03 %) of this polymer. This result is consistent
with  the  earlier  reports  suggesting  that  the  unimers  of  poloxamer  block  copolymers  are
responsible for the inhibition of P-gp in the cells (32, 21, 22). At higher concentrations of
poloxamer 185 (0.1 % - 1 %), the Rho-123 levels decrease. This effect of high poloxamer 185
concentrations is believed to be due to incorporation of the Rho-123 in the poloxamer micelles
resulting in the decrease in the amounts of the free Rho-123 available for diffusion into the cells
(21). The four cell lines in the present study were exposed to a maximal uptake of Rho-123 at
0.01 % poloxamer 185. However, Caco-2 cell lines showed the lowest levels in the uptake of
Rho-123 since this cell line displays the highest P-gp expression. Surprisingly, the GS-9L cell
line, the next in the range of higher P-gp expression, showed a comparable Rho-123 uptake to
RG-2 and F-98 cell lines.Results
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Polysorbate 80
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Figure 26. Rho-123 uptake in GS-9L, F-98, RG-2, and Caco-2 cell lines by FACS analysis. The
effect of polysorbate 80 on the Rho-123 uptake was measured at different concentrations
In  the  case  of  polysorbate  (Figure  26),  the  accumulation  of  Rho-123  also  increased  in  a
concentration-dependent manner. However, this effect was not seen at low concentrations the
Rho-123 in contrast to poloxamer 185. Additionally, the uptake of Rho-123 after polysorbate 80
was considerable lower than with poloxamer 185. Above a polysorbate concentration of about
0.001 % (0.01 % in the case of the GS-9L cell line) a significant fluorescence increase occurred
peaking at 0.1 % in all cell lines. Above this concentration the uptake of Rho-123 started to
diminish.
The three glioma cell lines achieved similar Rho-123 concentrations whereas the Caco-2 cell
line again showed the lowest values of fluorescence, as with poloxamer 185.Results
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Figure 27. Rho-123 uptake in GS-9L, F-98, RG-2, and Caco-2 cell lines by FACS analysis. The
effect of Verapamil on the Rho-123 uptake was measured at different concentrations
No concentration-dependent effect was visible with Verapamil. The three glioma cell lines again
yielded the highest mean fluorescence values, whereas Caco-2 cell line showed the lowest
Rho-123 uptake.
Unexpectedly, the accumulation of Rho-123 again was not significantly different between the
resistant GS-9L cell line and the two sensitive cell lines, RG-2 and F-98, as in the case of
doxorubicin.Discussion
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5  Discussion
The potential of poly(butyl cyanoacrylate) nanoparticles to be used as a doxorubicin carrier
was evaluated in an in vitro cytotoxic study, by comparing the cytotoxicity of doxorubicin in
solution and doxorubicin-loaded poly(butyl cyanoacrylate) nanoparticles (Dox-PBCA-NP). For
this purpose, the GS-9L, F-98 and RG-2 rat glioma cell lines were employed as glioma models.
5.1 Cytotoxicity  study  of  doxorubicin  and  doxorubicin
formulations.
At first, the growth inhibitory effect of doxorubicin alone was tested in the different glioma
cell lines at doxorubicin concentrations ranging from 0.1 µg/ml to 5 µg/ml. A concentration-
dependent decrease in the viability of the three cell lines was clearly observable already at lower
concentrations of doxorubicin. However, the IC50 of the three cell lines, GS-9L, RG-2, and F98,
was different in the three assays, MTT, LDH, and ATP, which measure different biochemical
parameters as indicators for cell death (see below).
On the other hand, the IC50 values showed a concordance between the three assays, indicating
clearly that the GS-9L cells display the highest resistance towards free doxorubicin, visible in all
three assays. RG-2 exhibited the lowest resistance in the LDH assay, whereas the F-98 showed
the lowest resistance in the ATP assay. No significant difference between RG-2 and F-98
appeared in the MTT test.
As described as in the Results section, the cytotoxic effect of the poly(butyl cyanoacrylate)
polymer was assessed by incubating the cell lines with different concentrations of unloaded
PBCA-NP. The maximal concentration of polymer used, 15 µg/ml, did not induce any significant
cytotoxic effects in all three different assays (MTT, LDH, and ATP). Therefore, it was assured
that this concentration of unloaded nanoparticles, which was not exceeded in the following
experiments did not exert any toxic effect on the cell lines tested. Thus, the decrease of the
viability showed in the following treatment of the cells with Dox-PBCA-NP was only due to the
cytotoxic activity of doxorubicin adsorbed onto the nanoparticles, indicating a high efficacy of
the loaded nanoparticles.Discussion
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The cytotoxicity of doxorubicin compared to doxorubicin adsorbed on PBCA-NP was analyzed
only using the MTT, and LDH assays because the ATP assay was not available any more.
Comparing  the  results  between  the  uncoated  and  surfactant-coated  Dox-PBCA-NP  and
doxorubicin solution, in general at equivalent concentrations of doxorubicin a higher decrease in
viability of the cells was observed after incubation with nanoparticle-bound doxorubicin than
after incubation with doxorubicin in solution, demonstrating an enhanced efficacy against the
cancer  cells  enabled  by  the  nanoparticles.  A  pronounced  decrease  of  the  viability  clearly
occurred also with the nanoparticles at lower concentrations of doxorubicin. However, as
previously  indicated,  the  coating  of  the  nanoparticles  with  the  surfactants  rendered  the
nanoparticle surface more hydrophilic, which in turn obstructed their interaction with the cellular
membranes. This effect is comparable to the so-called stealth effect: in in vivo experiments (97,
98)  the  capacity  of  poloxamine  908-coated  nanoparticles  and  poloxamer  188-coated
nanoparticles  was  already  shown  to  prevent  or  retard  the  opsonization  by  macrophages
because of the steric and the hydrophilic modification. As a result, the nanoparticles exhibited
long-circulating properties. However they were still not able to increase the brain concentration
of nanoparticles-bound drugs, because they were unable to overcome the efflux mechanism
present in the membranes of the brain endothelial cells. On the other hand, further in vivo
experiment demonstrated the ability of nanoparticles coated with polysorbate 80 to successfully
overcome these mechanisms reaching the brain, which means that polysorbate 80 was able to
interact with the cellular membrane. In our results, with the exception of polysorbate 80, no
distinct difference in efficiency was observable between uncoated and coated Dox-PBCA-NP.
The influence of the different surfactant coatings of the unloaded PBCA-NP on the viability of
the three cell lines was not relevant, except for the coating with polysorbate 80 in the RG-2 cells
in the LDH assay. The different coatings of the Dox-PBCA-NP in general did not show any
significant enhancement of the cytotoxicity of doxorubicin. Only some cases, the polysorbate
80-coated Dox-PBCA-NP exhibited a marked dose-dependent effect.
5.2 The use of viability assays to determine the cytotoxic effects
The results in Figure 9 and Figure 10 as well as those mentioned above with doxorubicin
solution alone (Fig. 7) demonstrated that the viability of the three cell lines differed according to
the assay used.Discussion
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The  sensitivity  of  these  cytotoxicity  assays  used  differed  depending  on  the  difference  in
mechanisms measured by these assays. Briefly, in the MTT assay, tetrazolium (MTT) salt is
added to the media and upon internalizing into the cells is reduced to a blue product by the
mitochondria dehydrogenase into the mitochondria. In the LDH assay, the amount of LDH a
cytosplamic enzyme is determined, which is released after cellular membrane damage from the
cytosol into the extracellular media. This enzyme is quantified by its property to catalyze the
reduction of lactate to a formazan. In the ATP assays, the amount of the metabolic ATP
contained  in  the  cells  is  used  to  give  the  conversion  from luciferin to oxiluciferin with the
corresponding emittance of light, which corresponds to the amount of ATP, and therefore, to
the number of viable cells.
Fischer D. et al., 2003 already carried out a comparative in vitro study where the cytotoxicity of
different substances was analysed looking for diverse toxic effects on the cells. They searched
for specific intracellular effects on the mitochondrial and metabolic activity (MTT assay) as well
as for membrane damage by the release of lactate dehydrogenase (LDH assay), finding a
correlation between the results obtained in both assays. In contrast, in our study, we looked for
cellular survival. Therefore, the cells were subjected to the same conditions during the entire
incubation procedure, following a standard protocol for the three assays to determine the
cellular survival with regard to their mitochondrial activity, their LDH activity, and the amount of
ATP in these cells. Consequently, it may be stated that the decrease of the viability given as a
decrease of the mitochondrial functionality differed to the viability given as a decrease in the
LDH activity or as an ATP decrease.
Weyermann J. et al. (2005) compared four cytotoxic detection assays in one cellular system
using three agents, Triton X-100, chloroquine, and sodium azide, and they concluded that the
sensitivity of the cytotoxic assay used differed depending on the different mechanism, which
leads to cell death. They also found differences in the viability of the treated cells depending on
the test agent. Correspondingly, in our study, the sensitivity of the cytotoxic assay used also
differed depending on the different mechanisms. Only one cytotoxic agent, doxorubicin, was
analysed in the three cytotoxic assays in three different cell lines, thereby the differences in the
sensitivity could be additionally highlighted by the variability of the cell lines.
The  different  sensitivity  of  the  different  parameters  measured  by  the  three  assays,  the
mitochondrial activity (MTT assay), the LDH activity (LDH assay) and the ATP content (ATP
assay) of the surviving cells was responsible for the variability of the results in the cellular viability
after the drug exposure between these assays.Discussion
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5.3 Multidrug resistance in the used in vitro glioma model
The results of the present study also showed that the three glioma cell lines additionally
responded differently to the doxorubicin action, presumably due to a different drug uptake into
these cells. Previous extensive studies have identified mechanisms through which tumour cells
escape the cytotoxic effects of a variety of chemotherapeutic drugs. The cellular resistance to
chemotherapy is multifactorial and may be affected by the cell cycle stage, proliferation status,
biochemical mechanisms (such as detoxification), cellular drug transport (influx, efflux, and
retention),  and  DNA  replication  and  repair  mechanisms.  The  resistance  to  multiple  drugs,
referred to as multidrug resistance (MDR) is a major impediment to the successful treatment of
various  human  cancers.  MDR  is  cell  resistance  not  to  single  substance  but  to  numerous
substances  characterized  by  different  mechanisms  of  action  and  by  different  chemical
structures. In some types of tumours, multidrug resistance is inherited, while in others it is
acquired.
In  this  study,  we  focused  on  the  cellular  multidrug  resistance  caused  by  a  decrease  of
doxorubicin accumulation by the tumour cells. The mechanism of this drug efflux from the cells
is mediated by the activity of transpoter proteins, i.e., P-glycoprotein (P-gp), transporter of the
MRP family, and some others proteins.
Since the present cytotoxic study showed a variable resistance to doxorubicin in the tested
glioma cell lines and since doxorubicin is a P-gp substrate, it was decided to analyze this
resistance investigating the P-gp expression in these cell lines, GS-9L, RG-2, and F-98. Indeed,
the P-gp expression of the three cell lines was different, showing the highest P-gp expression in
the  GS9L  cells,  and,  correspondingly,  a  lower  doxorubicin  uptake  and  lower  doxorubicin
cytotoxicity in this cell line. Therefore, the variable degree at the protein expression level in the
GS-9L, RG-2, and F-98 cell lines was responsible for the different resistance. With a higher P-
gp expression, the uptake of doxorubicin into the cells was decreased as it was shown by
FACS analysis, increasing the number of surviving cells after a doxorubicin exposure.
The analysis of the P-gp expression in the glioma cell lines, which corroborated the results
obtained by the doxorubicin cytotoxicity analysis. A Western blot confirmed the high expression
of  the  P-gp  in  the  cellular  membrane  of  the  GS-9L  cell  line,  corresponded  with  the  high
resistance towards the doxorubicin action by these cells. The weaker expression of P-gp in the
RG-2 and F-98 cell lines corresponded to the high sensitivity that both cell lines exhibited
towards treatment with doxorubicin. The P-gp-related sensitivity or insensitivity of the three cell
lines was reflected in all three cytotoxicity assays the MTT, the LDH, and ATP assays coincidedDiscussion
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in the different resistance displayed by the cell lines.
5.4  The use of poloxamer 185 and polysorbate 80 to overcome
the multidrug resistance of glioma cell lines
One of the major failures in cancer therapy is the simultaneous cellular resistance to
multiple drugs presented by the cell tumours. The mechanisms by which tumour cells become
resistant to multiple chemotherapeutic drugs are still poorly understood. However the numerous
strategies to overcome these resistance mechanisms resulted in encouraging results (6, 59, 86,
87). One of these strategies was the employment of various types of nanoparticles (59, 60).
As previously described, the expression of the P-glycoprotein on the cellular membrane of the
glioma cell lines was responsible for the avoidance of the doxorubicin entry into the cells and
therefore the blocking out of the drug action. The P-gp inhibitors block the P-gp-mediated
tranport of the drug out of the cells and consequently, facilite its intracellular accumulation and
consequently, increasing its efficacy.
A number of studies demonstrated a rather effective P-gp inhibition activity of the pluronic block
copolymers surfactant (5, 6, 8, 9). However, one of the most outstanding known poloxamers as
P-gp inhibitor is poloxamer 185. Poloxamer 185 posses the structural characteristics required
for  maximal  impact  on  drug  efflux  transporter  activity  (89).  Previous  work  reported  that
poloxamer  185  increases  accumulation  of  the  MRP  (multidrug  resistance  related  protein)
substrates vincristine and doxorubicin (70).
Since  in  the  above  cytotoxicity  study  polysorbate  80  showed  an  improvement  of  the
doxorubicin action and since it has been also described as a P-gp inhibitor, it was also used as
a second P-gp inhibitor in addition and comparison to the poloxamer 185.
The treatment of the cells with poloxamer 185 and polysorbate 80 doxorubicin-formulations led
to different results. The expected inhibition of the efflux of doxorubicin in many cases was
clearly seen after treatment with poloxamer 185, which was especially significant in cell lines
with a high P-gp-expression, such as GS-9L. In the cell lines with a low P-gp expression, such
as RG-2 and F-98, the effect of poloxamer 185 on the transport of doxorubicin was slight to nil.
This demonstrated that the presence of poloxamer 185 had an important effect on the transport
of doxorubicin into the glioma cells with a significant P-gp expression, i.e. doxorubicin resistant
cells. Poloxamer 185 not only enhanced the transport of doxorubicin solution into the cells butDiscussion
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also that of nanoparticles-bound drug, although to a lower degree.
On the other hand, the polysorbate 80 formulations influenced the doxorubicin internalization
very little and in some cases even a lower transport than for the doxorubicin in solution was
observed. This effect was observable in all the cell lines, although to a different degree. For
instance, the RG-2 cell line seems to be affected lesser by the polysorbate 80 action than the F-
98 cell lines in which the accumulation of doxorubicin was hardly perceptible after the treatment
with polysorbate 80-doxorubicin formulations, as shown by CLSM.
As said above, the capacity of poloxamer 185 to increase the intracellular doxorubicin in P-gp-
expressing cells was clearly shown in the GS-9L cell line. In contrast, in the low P-gp expressing
cell lines, RG-2 and F-98, no significant difference in the transport of doxorubicin by the
presence of poloxamer 185 was visible. Given that in these cell lines the doxorubicin did not find
any resistance to its internalization due to the absence of a high P-gp expression on the
membrane, doxorubicin enters the cell by passive diffusion. On the other hand, the resistance
to doxorubicin internalization displayed by the GS-9L cells due to their P-gp expression was
overcome  by  the  effect  of  poloxamer  185,  blocking  the  extrusion  out  the  cells  of  the
doxorubicin, and increasing its intracellular accumulation.
The different results obtained after the treatment with the two surfactants, poloxamer 185 and
polysorbate 80, led us to look into possible mechanism that could lead to these differences.
In  the  literature  there  are  differences  in  the  surfactant  action  on  the  cellular  membranes.
Therefore the effects of poloxamer 185 and polysorbate 80 solutions on the cellular membrane
were studied in the present investigation, using confocal microscopy. The cellular membranes
of GS-9L cells were observed after treatment with different concentrations of poloxamer 185
and polysorbate 80 solutions. The changes in the membrane were rather visible in the case of
the polysorbate 80, leading to stark toxic effects on the cells at a 1 % concentration. In contrast
to poloxamer 185, no visible change was observable at the same concentrations and after the
same incubation conditions.
For this reason, the influence of polysorbate 80 on doxorubicin uptake and accumulation may
be  a  direct  effect  on  the  cellular  membrane,  leading  to  a  loss  of  the  integrity  at  higher
concentrations and, therefore, to an uncontrolled transport in and out of the cells. That could
explain the low intracellular internalization of doxorubicin after polysorbate 80 incubation in the
cells.
In first studies, Batrakova et al (8, 22) concluded that the inhibition of P-gp by poloxamer 185
(Pluronic® P85) involves two effects: one, a decreasing interaction or affinity of P-gp with
respect to both ATP and the drug molecules; second, a depletion of intracellular ATP (energy
depletion) in the endothelial cells of the brain microvessel.Discussion
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This fact assures that poloxamer 185 has a direct effect on the functionality of P-gp rather than
on the cellular membrane, which may explain the intact membrane after the incubation with
poloxamer 185 (Fig. 22).
The capacity of poloxamer 185 to increase the internalization of doxorubicin into the cells may
be used to improve the doxorubicin action on the tumour cells, decreasing the viability of the
tumour cells after poloxamer 185-doxorubicin formulation treatment. Hence, cell survival after
treatment with poloxamer 185- and polysorbate 80-doxorubicin formulation was studied.
The analysis carried out in the glioma cell lines as well as in the Caco-2 cell line suggested that
the formulations containing polysorbate decreased the viability of the all cell lines in a greater
manner than the poloxamer 185 formulations. On the first glance, this is surprising because
poloxamer 185 improved the doxorubicin internalization into the cells, thereby the activity of
doxorubicin should be also improved. Moreover, the decrease of the viability after the treatment
with polysorbate formulation is not corresponding with the low accumulation of doxorubicin as
previously showed. On the other hand, the low accumulation of doxorubicin in the cells after
treatment with the polysorbate 80-containing formulations should not decrease the cell viability
to a great extend.
However, the study of the membrane integrity after treatment with polysorbate 80 indicated a
significant  deteriorated  membrane,  and  even  more  toxic  effects  on  the  cells  at  higher
concentration. So it can be concluded that the effect of polysorbate 80 formulations on the
viability of the cells is greater because it is the combination of the two toxic effects: doxorubicin
action and polysorbate 80 cellular membrane damage (Fig. 23).
5.5 The concentration-dependent effect of poloxamer 185 and
polysorbate 80 on the P-gp inhibitory function.
One  important  factor  for  overcoming  the  drug  resistance  by poloxamer  185  is  the
concentration. Therefore, the effect of poloxamer 185 concentration on the accumulation of
Rho123 in the three glioma cell lines, GS-9L, RG-2 and F-98 cell lines was determined. The
concentration effects of poloxamer 185 also were compared with the concentration effects of
polysorbate 80 and verapamil, a known P-gp substrate.
In the range of concentrations used a concentration-dependent increase in the uptake of
Rho123 was observed in all cell lines, reaching a maximal value at 0.01 % concentration to theDiscussion
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CMC poloxamer 185 showing its maximal effect and decreasing at concentrations above the
CMC. This result is consistent with previous reports suggesting that the unimers of poloxamer
185 (single chains of block copolymers) are responsible for the inhibition of P-gp efflux transport
out of the cells (22, 25, 29). The decrease of Rho123 at higher concentrations above of the
CMC of poloxamer 185 is believed to be due to incorporation of the drug into poloxamer 185
micelles, which in turn decreases the amount of free drug available to diffuse into the cells.
In the case of polysorbate, the accumulation of Rho123 also increased in a concentration-
dependent manner. Polysorbate exerted the greatest effect on the Rho123 uptake at 0.1 % for
each cell line. Above 0.1 % the uptake of Rho123 also started to diminish. This decrease,
however, may not only be due to micelle incorporation but also may be due to the toxic effects
by polysorbate at high concentrations as indicated by the study of the integrity of the cellular
membrane, where at 0.1 % these effects appeared and at 1 % toxic effects were totally evident.
Thus, the concentration-dependent effect of poloxamer 185 may justify the fact that in the GS-
9L cells after the treatment with P185-Dox-PBCA-NP did not yield a high enhancement of the
doxorubicin accumulation as it was observed after the treatment with doxorubicin+P185. Taken
into consideration that both formulations contain the same concentration of poloxamer 185, in
the  case  of  P185-Dox-PBCA-NP  formulation poloxamer  185  acted  as  coating  that  could
decrease the concentration of free unimers able to inhibit the P-gp-mediated transport of
doxorubicin, whereas in the case of doxorubicin+P185, the concentration of free unimers would
be higher and consequently nearer to 0.01% poloxamer 185, at which concentration poloxamer
exerts its highest effect.Discussion
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Figure 28. Mode of action of coated nanoparticles
In  conclusion,  poloxamer  185  noteworthy  enhanced  the  transport  of  the  anthracycline,
doxorubicin,  in  doxorubicin-resistant  cell  lines,  such  as  the  GS-9L  and  the  Caco-2  by
overcoming the P-gp-mediated efflux. However this enhancement in the doxorubicin transport
did not occur in doxorubicin-sensitive cell lines, such as the RG-2 and the F-98. Moreover, after
incubation with different concentrations of poloxamer 185, the cellular membrane of GS9L did
not show any visible alteration. Therefore, a selective interaction with P-gp rather than an
unspecific  membrane  alteration  provoked  the  increase  in  the  doxorubicin  transport  in  the
doxorubicin-resistant cells. Batrakova et al. demonstrated using the hydrophobic membrane
probe DPH, that poloxamer 185 induced changes in the microviscosity of the cell membranes
in BBMEC and they also reported that similar changes were observed in the cancer cells
treated with Pluronic® block copolymers (100).
Therefore, it is suggested that poloxamer 185 may have a double effect: through the ATP
depletion and membrane fluidization, and that it seems very important that Pluronic® is bound
to the membranes during the entire procedure. The removal of poloxamer 185 from the medium
suggested that in the absence of the interaction of the poloxamer 185 with the P-gp- containing
membranes the efflux system was inhibited insufficiently.
However, contrary to poloxamer 185, in the case of polysorbate 80 did not show a clear
selective interaction with the P-gp. The entry of doxorubicin into the cells doxorubicin-resistantDiscussion
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cells did not increase after the treatment with the polysorbate 80 formulations, whereas with
Rho-123  a  concentration  dependent  increase  occurred  after  incubation  at  certain
concentrations of polysorbate 80. The stark changes in the integrity of the cellular membrane
observed after treatment with polysorbate 80 solutions indicated an important interaction of the
surfactant  with  the  membrane  and  even  more  a  loss  of  the  membrane  integrity  at  1  %
concentration.Summary
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Summary
The use of doxorubicin is a promising approach for the treatment of glioma tumours
since  it  is  a  very  effective  neoplastic  agent.  However,  one  problem  faced  by  the  use  of
doxorubicin for the treatment of brain tumours is the fact that doxorubicin is a substrate of efflux
pump proteins, such as P-glycoprotein (P-gp), which is located on the luminal side of the brain
capillary endothelium and in many tumour cells. Therefore, these transporters are responsible
for the multidrug resistance (MDR) in the case of brain tumours, pumping substances like
doxorubicin out of the cell, and blocking their transport into the tumour cell. A demonstrated
strategy to enhance the doxorubicin delivery into the brain is the use of nanoparticles.
The present in vitro study analyzed the transport of different doxorubicin formulations in three
glioma models, the GS-9L, the RG-2 and the F-98 glioma cell lines. It was shown, that the
treatment  of  doxorubicin  bound  to  poly(butyl  cyanoacrylate) nanoparticles decreased the
viability of the three glioma cell lines significantly in comparison to doxorubicin in solution,
indicating an improvement of the nanoparticles-bound doxorubicin transport into the cells.
The modification of the nanoparticles surface with different surfactants even may enhance the
delivery  of  the  drug  into  the  cells.  Searching  for  an  improvement  of  the  doxorubicin
internalization, the nanoparticles surface was modified using polysorbate 80, poloxamer 188,
and poloxamine 908 surfactants. Poloxamer 188 and polaxamine 908-modified nanoparticles
did not yield a significant enhancement of the doxorubicin internalization. In contrast, the
treatment  with  polysorbate  80-modified  nanoparticles  led  in  some  cases  to  a  significant
decrease of cancer cell viability.
The cytotoxicity of doxorubicin formulations was analyzed using three cytotoxicity detection
assays: the MTT, the LDH, and the ATP assays. These three assays showed a significant
variability in the results of viability. The different sensitivity of the different parameters measured
by the three assays, the mitochondrial activity (MTT assay), the LDH activity (LDH assay) and
the ATP content (ATP assay) of the surviving cells was responsible for the variability of the
results in the cellular viability after the drug exposure between these assays. Moreover, the
differences in the sensitivity of the three assays could be additionally highlighted by the variability
of the three cell lines used.
Moreover,  the  results  of  the  present  study  also  showed  that  the  three  glioma  cell  lines
responded differently to the doxorubicin action, presumably due to a different drug uptake intoSummary
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these cells. Previous extensive studies have identified mechanisms through which tumour cells
escape the cytotoxic effects of a variety of chemotherapeutic drugs. The cellular resistance to
chemotherapy is multifactorial and may be affected by the cell cycle stage, proliferation status,
biochemical mechanisms (such as detoxification), cellular drug transport (influx, efflux, and
retention), and DNA replication and by repair mechanisms. The resistance to multiple drugs,
referred to as multidrug resistance (MDR) is a major impediment to the successful treatment of
various  human  cancers.  MDR  is  cell  resistance  not  to  single  substance  but  to  numerous
substances  characterized  by  different  mechanisms  of  action  and  by  different  chemical
structures. In some types of tumours, multidrug resistance is inherited, while in others it is
acquired.
In this study, we focused on the cellular multidrug resistance causing a decrease of doxorubicin
accumulation by the tumour cells. The mechanism of this drug efflux from the cells is mediated
by the activity of transpoter proteins, i.e., P-glycoprotein (P-gp), transporter of the MRP family,
and some others proteins. Thus, the different responses to doxorubicin shown were due to the
fact that the transport of this drug into the glioma cells was subjected to the action of the P-
glycoprotein expressed on their cellular membrane. A higher level of the P-gp expression
correlated with a weaker response towards the doxorubicin treatment. The GS-9L cell line
showed a significant higher level of P-gp expression than the F-98 and RG-2 cell lines, and
consequently, the GS-9L cell line presented the highest resistance to doxorubicin with the
highest viability after doxorubicin treatment.
As above mentioned, one of the major failures in cancer therapy is the simultaneous cellular
resistance to multiple drugs presented by the cell tumours. The mechanisms by which tumour
cells become resistant to multiple chemotherapeutic drugs are still poorly understood. However,
the numerous strategies to overcome these resistance mechanisms resulted in encouraging
results. One of these strategies was the employment of nanoparticles coated with different
surfactants,  where  one  of  the  components  may  function  by  overcoming  these  resistance
mechanisms.
As previously described, the expression of the P-glycoprotein on the cellular membrane of the
glioma cell lines was responsible for the avoidance of the doxorubicin entry into the cells and,
therefore, the blocking out of the drug action. The P-gp inhibitors block the P-gp-mediated
transport of the drug out of the cells and consequently, facilite its intracellular accumulation
thereby, increasing its efficacy.
A number of studies demonstrated a rather effective inhibition of P-gp activity by the pluronic
block copolymers surfactant (5, 6, 8, 9). In this group of surfactants, one of the mostSummary
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outstanding poloxamer known as P-gp inhibitor is poloxamer 185. Poloxamer 185 posses the
structural characteristics required for maximal impact on drug efflux transporter activity (89).
Previous work reported that poloxamer 185 increases accumulation of the MRP (multidrug
resistance related protein) substrates vincristine and doxorubicin (70).
For this purpose, the use of the P-gp inhibitor, poloxamine 185 was studied. The use of
poloxamer 185 resulted in an enhancement of the uptake as well as of the accumulation of
doxorubicin  into  the  cells.  The  effect  of  poloxamer  185  on  the  doxorubicin  uptake  was
especially pronounced in the case of doxorubicin-resistance cells, such as the GS-9L cell line.
In some cases, the presence of the nanoparticles formulation further improved the uptake.
The use of a P-gp inhibitor in combination with chemotherapeutic agents may improve their
efficacy. Because of the wide spectrum of substances acting as P-gp inhibitors, in many cases
the exact inhibitory mechanisms still remain unclear. The non-ionic surfactant polysorbate 80
has been shown to increase the permeability of certain transport markers in Caco-2 cells as well
as  improving  the  permeation  of  proteins  susceptible  to  P-gp-mediated  efflux.  Poloxamer
(Pluronics®) copolymers have also been shown to enhance the diffusion of compounds such as
doxorubicin  across  model  lipid  bilayers.  These  investigations  suggest  that  surfactant
interactions  with  membranes  leading  to  increased  membrane  permeability  may  play  an
important role in enhancing the transmembrane diffusion of a P-gp substrate and its intracellular
accumulation, independently of the inhibitory effects of these surfactants on P-gp. However, in
our previous experiments, it was observed that the uptake of doxorubicin was increased by
poloxamer 185 in cells with a higher P-gp expression level, whereas polysorbate 80 even led to
a reduction in the intracellular accumulation of doxorubicin in the doxorubicin sensitive-cell lines
RG-2 and F-98. The evaluation of a described potential P-gp inhibitor, polysorbate 80, did not
show an important improvement in doxorubicin uptake in the P-gp-expressing cell line, GS-9L.
On  the  other  hand,  the polysorbate 80-Dox-PBCA nanoparticles formulation decreased the
viability of the glioma cells to greater extend than the poloxamer185-Dox-PBCA nanoparticles.
Although,  the  P-gp  inhibition  was  undoubtedly  higher  in  the  presence  of  poloxamer  185,
polysorbate 80 showed a significant effect on the disruption of the cellular membrane, resulting
in an important cellular viability decrease. It appears that poloxamer 185, on the other hand,
exhibits  a  direct  effect  on  the  functionality  of  the  P-gp  protein,  which  would  be  of  great
importance for the sensitization of resistant cancer cells.
The concentration of poloxamer 185 had a very important influence on the inhibitory effect on
the P-gp-mediated transport mechanism. Therefore, the effect of poloxamer 185 concentration
on the accumulation of Rhodamine 123, a known P-gp substrate, in the three glioma cellSummary
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lines, GS-9L, RG-2, and F-98 was determined. The concentration effect of poloxamer 185 also
was compared with the concentration effects of polysorbate 80 and Verapamil, a known P-gp
substrate. The accumulation of Rhodamine-123 increased in a range of concentration from
0.001 % to 0.01 %, whereas at 0.1 % poloxamer 185 the accumulation significantly decreased.
A maximal Rho-123 accumulation was reached at 0.01 % poloxamer  185.  In the case of
polysorbate, the accumulation of Rho123 also increased in a concentration-dependent manner.
Polysorbate exerted the greatest effect on the Rho123 uptake at 0.1 % for each cell line. Above
0.1 % the uptake of Rho123 also started to diminish. This decrease, however, may not only be
due to micelle incorporation but also may be due to the toxic effects by polysorbate at high
concentrations as indicated by the study of the integrity of the cellular membrane, where at 0.1
% these effects appeared and at 1 % toxic effects were totally evident.
In  conclusion,  poloxamer  185  noteworthy  enhanced  the  transport  of  the  anthracycline,
doxorubicin,  in  doxorubicin-resistant  cell  lines,  such  as  the  GS-9L  and  the  Caco-2  by
overcoming the P-gp-mediated efflux. However this enhancement in the doxorubicin transport
did not occur in doxorubicin-sensitive cell lines, such as the RG-2 and the F-98. Moreover, after
incubation with different concentrations of poloxamer 185, the cellular membrane of GS9L did
not show any visible alteration. Therefore, a selective interaction with P-gp rather than an
unspecific  membrane  alteration  provoked  the  increase  in  the  doxorubicin  transport  in  the
doxorubicin-resistant cells. Batrakova et al. demonstrated using the hydrophobic membrane
probe DPH, that poloxamer 185 induced changes in the microviscosity of the cell membranes
in BBMEC and they also reported that similar changes were observed in the cancer cells
treated with Pluronic® block copolymers (100). This author (8, 22) also demonstrated that the
inhibition of P-gp by poloxamer 185 (Pluronic® P85) involves two effects: one, a decreasing
interaction or affinity of P-gp with respect to both ATP and the drug molecules; second, a
depletion of intracellular ATP (energy depletion) in the endothelial cells of the brain microvessel.
This fact assures that poloxamer 185 has a direct effect on the functionality of P-gp rather than
on the cellular membrane, which may explain the intact membrane after the incubation with
poloxamer 185 (Fig. 22).
Therefore, it is suggested that poloxamer 185 may have a double effect: through the ATP
depletion and membrane fluidization, and that it seems very important that Pluronic® is bound
to the membranes during the entire procedure. The removal of poloxamer 185 from the medium
suggested that in the absence of the interaction of the poloxamer 185 with the P-gp- containingSummary
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membranes the efflux system was inhibited insufficiently.
However, contrary to poloxamer 185, in the case of polysorbate 80 did not show a clear
selective interaction with the P-gp. The entry of doxorubicin into the cells doxorubicin-resistant
cells did not increase after the treatment with the polysorbate 80 formulations, whereas with
Rho-123  a  concentration  dependent  increase  occurred  after  incubation  at  certain
concentrations of polysorbate 80. The stark changes in the integrity of the cellular membrane
observed after treatment with polysorbate 80 solutions indicated an important interaction of the
surfactant  with  the  membrane  and  even  more  a  loss  of  the  membrane  integrity  at  1  %
concentration.
In conclusion, the association of poloxamer 185 with doxorubicin in solution and the poloxamer
185 coated-nanoparticle formulation of doxorubicin allowed overcoming the P-gp-mediated
transport. Important requirements for that were the concentration of poloxamer 185 and the
direct effect of poloxamer 185 displayed on the P-gp activity.Zusammenfassung
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Zusammenfassung
Die Verwendung von Doxorubicin stellt einen wichtigen therapeutischen Ansatz in der
chemotherapeutischen Behandlung von Tumoren gliomalen Ursprungs dar, da sich Doxorubicin
bereits als sehr effektiver neoplastischer Wirkstoff erwiesen hat. Es besteht jedoch das Problem,
dass Doxorubicin durch Multidrug-Resistenzproteine, wie P-gp sowohl aus den Endothelzellen
der  Blut-Hirn  Schranke  als  auch  aus  Gerhirntumorzellen  entfernt  wird.  Diese  sind  in  der
Membran dieser Zellen lokalisiert und pumpen Doxorubicin und andere Substrate in einem ATP-
abhängigen Prozess aus der Zelle. Aus diesem Grund ist P-gp für die Multidrug-Resistenz bei
Gehirntumoren verantwortlich, indem es Substanzen wie Doxorubicin aus den Zellen pumpt
oder ihren Eintritt in das Zellinnere blockiert. Eine Möglichkeit die Doxorubicin-Applikation im
Gehirn zu verbessern ist die Verwendung von Nanopartikeln.
Die vorliegende Arbeit befasste sich mit dem Transport verschiedener Anwendungsformen von
Doxorubicin in drei Glioma-Modelle, den GS-9L, den RG-2 und die F-98 Gliomazellen. Hierbei
konnte gezeigt werden, dass die Wirkung von Doxorubicin durch die Bindung an Poly(butyl-
cyanoakrylat)-Nanopartikel im Vergleich zu freiem Doxorubicin in Lösung signifikant gesteigert
werden konnte. So konnte die Anzahl an über lebenden Zellen nach einer Behandlung der
Glioma Zelllinien GS-9L, RG-2 und F-98 mit Doxorubicin-beladenen Nanopartikeln signifikant
erniedrigt  werden,  was  für  eine  erhöhte  effektive  Doxorubicin-Konzentration  in  den  Zellen
spricht.
Die Modifikation der Oberfläche der Nanopartikel mit unterschiedlichen Surfaktantien könnte
das Einbringen von Doxorubicin in die Zielzellen zusätzlich erhöhen. Bei der Suche nach einer
verbesserten Doxorubicin-Internalisation wurde die Oberfläche der Nanopartikel mit Tensiden
wie Polysorbat 80, Poloxamer 188 und Poloxamin 908 modifiziert. Die mit Poloxamer 188 und
Polaxamin  908  modifizierten  Nanopartikel  zeigten  keine  signifikante  Verbesserung  der
Doxorubicin-Internalisation in die Zellen. Im Gegensatz dazu konnte eine signifikante Reduktion
der lebenden Krebszellen durch die Behandlung mit Polysorbat 80-modifizierten Nanopartikeln
beobachtet werden.
Die  Zytotoxizität  der  verschiednen  Doxorubicin-Anwendungsformen  wurde  in  drei
verschiedenen Zytotoxizität-Analyseversuchen untersucht: den MTT-, LDH- und dem ATP-
Tests. In den unterschiedlichen Versuchen werden verschiedene Parameter gemessen, die
mitochondriale Aktivität (MTT-Test), die Laktatdehydrogenase Aktivität (LDH-Test) und der ATPZusammenfassung
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Gehalt  der  Zellen  (ATP-Test).  Die  verschiedenen  Parameter  besitzen  eine  unterschiedliche
Sensitivität,  wodurch  sich  die  Variabilität  der  Versuchergebnisse  erklären  lässt.  Diese
unterschiedliche Sensitivität wurde ferner in den Ergebnissen der drei verwendeten Zelllinien
deutlich.
Die vorgelegten Ergebnisse zeigen auch, dass die verschiedenen Zelllinien unterschiedlich auf
die  Doxorubicin Behandlung reagierten, welches wahrscheinlich mit einer unterschiedlichen
Wirkstoffaufnahme in Verbindung steht. Intensive Studien konnten Mechanismen identifizieren,
mit welchen Krebszellen die zytotoxischen Effekte einer Vielzahl von chemotherapeutischen
Wirkstoffen  umgehen.  Die  zelluläre  Resistenz  gegenüber  Chemotherapeutika  besitzt  eine
Vielzahl von Faktoren und könnte durch den Zellzyklusstatus, den Status der Proliferation,
biochemischen Mechanismen (wie z.B. Entgiftung), zellulärer Wirkstoff Transport (Influx, Efflux
und Retention) und DNA-Replikation sowie Reparaturmechanismen beeinflusst werden. Die
Resistenz  gegenüber  verschiedenen  Wirkstoffen,  welche  als  Multidrug  Resistenz  (MDR)
bezeichnet wird, ist ein wichtiger Faktor in der erfolgreichen Behandlung von menschlichen
Tumoren. MDR bedeutet nicht die Resistenz gegenüber einem einzelnen Wirkstoff sondern
schließt eine Vielzahl von Wirkstoffen ein, die sich sowohl in ihrer chemischen Substanzklasse
als auch in ihrem Wirkungsmechanismus unterscheiden können. In manchen Tumoren ist die
MDR bereits vorhanden, in anderen kann sie durch Mutationen erlangt werden.
In  der  vorliegenden  Studie  war  der  zelluläre  MDR-Mechanismus,  welcher  eine  reduzierte
Doxorubicin-Akkumulation in den Krebszellen zur Folge hatte, Fokus der Untersuchungen.
Der Mechanismus des Wirkstoffexports aus den Zellen wird von Transporterproteinen,  wie dem
P-Glykoprotein (P-gp), Transportern der MDR-Proteinfamilie und anderen Proteinen, vermittelt.
Die unterschiedlichen Wirkungen von Doxorubicin in den verschiedenen Zelllinien war darauf
zurückzuführen, dass Doxorubicin als Substrat von P-gp, welches sich in der Zellmembran der
Zellen befindet, aus den Gliomazellen transportiert wird. Hierbei korrelierte eine erhöhte P-gp
Expression  mit  einer  schwächeren  Doxorubicin-Wirkung.  Die  Zelllinie  GS-9L  zeigte  eine
signifikant höhere P-pg-Expression als die F-98- und RG-2-Zellen. Konsequenterweise wurde in
dieser  Zelllinie  die  höchste  Doxorubicin-Resistenz  ermittelt  mit  den  höchsten  Werten  an
überlebenden Zellen nach Doxorubicin-Behandlung.
Da der Transport von Doxorubicin aus den Glioma-Zellen mit der Aktivität des P-gp-Proteins
korreliert, konnte durch die Verwendung des P-gp-Inhibitors Poloxamer 185 eine verbesserte
Aufnahme und Akkumulation von Doxorubicin in den Zellen erreicht werden. Dieser Effekt der
verbesserten Doxorubicin-Aufnahme konnte besonders gut in den Doxorubicin-resistentenZusammenfassung
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GS-9L Zellen beobachtet werden. In einigen Fällen konnte auch eine verbesserte Aufnahme
durch die Verwendung der Nanopartikel beobachtet werden.
Wie oben dargestellt wurde, ist die Hauptursache einer nichtwirksamen Krebstherapie die
simultane Resistenz der Tumorzelle gegenüber verschiedenen Wirkstoffen. Der Mechanismus,
wodurch diese MDR erreicht wird, ist immer noch nicht ausreichend erforscht. Allerdings haben
bereits verschiedene Strategien die MDR zu überwinden ermutigende Erfolge erzielt. Eine dieser
Strategien  war  die  Behandlung  mit  Nanopartikeln,  deren  Oberfläche  mit  verschiedenen
Tensiden  modifiziert  war,  wobei  eines  dieser  Tenside  dazu   betragen  kann,  die
Wirkstoffresistenz zu überwinden.
Wie bereits beschrieben, war die Expression des P-gp Proteins in der Zellmembran dafür
verantwortlich, dass Doxorubicin nicht in die Krebszellen gelangen konnte, um seine Funktion
zu erfüllen. Mit Hilfe des P-gp-Inhibitors gelingt es die Funktion des Proteins zu blockieren,
wodurch  die  Doxorubicin-Anreicherung  in  den  Gliomazellen  und  eine  damit  verbundene
Wirkungssteigerung möglich wird.
Eine Reihe von Studien konnten einer recht effiziente Inhibition der P-gp Aktivität durch “pluronic
block copolymers surfactant” (5,6,8,9). In dieser Gruppe von Tensiden ist das Poloxamer,
welches am besten als P-gp Inhibitor beschrieben ist, Poloxamer 185. Poloxamer 185 besitzt
die  strukturellen Eigenschaften,  um  einen  maximalen  Einfluss  auf  die  Medikament  Efflux
Transportaktivität zu besitzen.
A number of studies demonstrated a rather effective P-gp inhibition activity of the pluronic block
copolymers surfactant (5, 6, 8, 9). However, one of the most outstanding known poloxamers as
P-gp inhibitor is poloxamer 185. Poloxamer 185 posses the structural characteristics required
for  maximal  impact  on  drug  efflux  transporter  activity  (89).  Previous  work  reported  that
poloxamer  185  increases  accumulation  of  the  MRP  (multidrug  resistance  related  protein)
substrates vincristine and doxorubicin (70).
Aus diesem Grund wurde die Verwendung eines P-gp-Inhibitors, Poloxamin 185, untersucht.
Die  Verwendung  von  Poloxamin  185  führte  zu  einer  erhöhten  Doxorubicin  Aufnahme  und
Akkumulation in den Gliomazellen. Der Effekt der Doxorubicin-Aufnahme war besonders in
Doxorubicin-resistenten  Zellen,  wie  GS-9L-Zellen,  erhöht.  In  einigen  Fällen  konnte  die
Doxorubicin-Aufnahme durch die Oberflächen-Beschaffenheit der Nanopartikel weiter erhöht
werden.Zusammenfassung
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Auch in der vorliegenden Arbeit führte die Verwendung von P-gp-Inhibitoren in Kombination mit
chemotherapeutischen  Agentien  zu  ermutigenden  Resultaten.  Trotzdem  bleibt  durch  das
grosse Spektrum an Substanzen, die in der Lage sind das P-gp Protein zu inhibieren, der
exakte Mechanismus der Inhibition weiterhin ungeklärt. Das nicht-ionische Tensid Polysorbat 80
konnte sowohl die Permeabilität von bestimmten Transportmarkern in Caco-2-Zellen erhöhen,
als auch die Permeabilität von Proteinen, die ein Substrat von P-gp-vermitteltem Export sind.
Für Poloxamer (Pluronics®) Copolymere konnte ebenfalls gezeigt werden, dass sie die Diffusion
von  Wirkstoffen  wie  Doxorubicin  über  Modellen  von  Doppellipidschichen  erhöhen.  Diese
Entdeckungen  lassen  vermuten,  dass  die  Tensid-Interaktionen  mit  Membranen  die
Membranpermeabilität erhöhen und auf diese Weise eine wichtiger Faktor in der Erhöhung der
Transmembrandiffusion eines P-gp Substrates und dessen Akkumulation in den Zielzellen sind,
unabhängig von der Inhibition des P-gp Proteins durch diese Tenside. In unseren bisherigen
Versuchen wurde beobachtet, dass die Aufnahme von Doxorubicin durch Poloxamer 185 in
Zellen mit starker P-gp Expression erhöht, wo hingegen durch die Behandlung der Doxorubicin-
sensitiven  Zellen  RG-2  und  F-98  mit  Polysorbat  80  die  Doxorubicin  Akkumulation  sogar
vermindert  wurde.  Ferner  konnte  die  Verwendung  von  Polysorbat  80  die  Aufnahme  von
Doxorubicin in GS-9L Zellen nicht erhöhen. Allerdings wurde die Zahl an lebenden Glioma Zellen
durch die Behandlung mit Polysorbat 80-Dox-PBCA Nanopartikeln stärker reduziert als durch
die Behandlung mit Poloxamer 185-Dox-PBCA Nanopartikeln. Obwohl der Effekt der P-gp
Inhibition in Gegenwart von Poloxamer 185 höher war, zeigte Polysorbat 80 einen starken Effekt
auf die Zellmembran, wodurch die Anzahl der lebenden Zellen stark vermindert werden konnte.
Poloxamer  185  scheint  hingegen  einen  direkten  Einfluss  auf  die  Funktionalität  von  P-gp
auszuüben, wodurch es von großer Bedeutung für die Sensitivierung bei der Chemotherapie
von resistenten Krebszellen sein könnte.
Die Höhe der Poloxamer 185-Konzentration ist hierbei der entscheidende Parameter um einen
inhibitorischen Effekt auf den P-gp-vermittelten Transportmechanismus zu erzreichen.
Die Akkumulation von Rhodamin-123 (Rho-123), einem bekannten P-gp Substrat, konnte durch
die Zugabe von 0,001 % bis 0,01 % stark erhöht werden, wobei ab einer Poloxamer 185-
Konzentration von 0,1 % sich die Rho-123 Akkumulation wieder signifikant reduzierte. Die
maximale Rho-123 Akkumulation wurde bei einer Konzentration von 0,01 % Poloxamer 185
erreicht.
Zusammenfassend lässt sich sagen, dass die gleichzeitige Applikation von Poloxamer 185 mit
Doxorubin in Lösung und die Poloxamer-umhüllten, Doxorubizin-beladenen Nanopartikel den P-Zusammenfassung
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pg-vermittelten Transport verhindern konnten. Eine wichtige Vorraussetzung hierfür ist  die
Poloxamer 185 Konzentration und die dadurch erzielten Effekte auf die P-gp Aktivität.Literature
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